##4070857
A	a	zz1
number	number	nn1
of	of	io
dramatic	dramatic	jj
breakthroughs	breakthrough	nn2
in	in	ii
the	the	at
neurobiology	neurobiology	nn1
of	of	io
addiction	addiction	nn1
have	have	vh0
occurred	occur	vvn
in	in	ii
the	the	at
past	past	jj
40	40	mc
years	year	nnt2
.	.	y
Two	two	mc
domains	domain	nn2
will	will	vm
be	be	vbi
highlighted	highlight	vvn
:	:	y
the	the	at
neurocircuitry	neurocircuitry	nn1
of	of	io
addiction	addiction	nn1
and	and	cc
the	the	at
molecular	molecular	jj
biology	biology	nn1
of	of	io
addiction	addiction	nn1
targets	target	nn2
.	.	y
The	the	at
neurebiological	neurebiological	jj
substrates	substrate	nn2
for	for	if
the	the	at
reinforcing	reinforcing	jj@
effects	effect	nn2
of	of	io
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
have	have	vh0
been	be	vbn
largely	largely	rr
identified	identify	vvn
both	both	rr
at	at	ii
the	the	at
initial	initial	jj_nn1
site	site	nn1
of	of	io
action	action	nn1
and	and	cc
in	in	ii
the	the	at
circuitry	circuitry	nn1
involved	involve	vvd_vvn
.	.	y
In	in	ii
human	human	jj_nn1
imaging	imaging	nn1_vvg
studies	study	nn2
,	,	y
decreases	decrease	vvz
in	in	ii
dopaminergic	dopaminergic	jj
function	function	nn1
have	have	vh0
been	be	vbn
identified	identify	vvn
as	as	ii
a	a	at1
key	key	jj
element	element	nn1
of	of	io
addiction	addiction	nn1
,	,	y
/ending		jj_nn1
support	support	nn1
for	for	if
research	research	nn1
on	on	ii
the	the	at
role	role	nn1
of	of	io
dopamine	dopamine	nn1
in	in	ii
addiction	addiction	nn1
.	.	y
Three	three	mc
novel	novel	jj
areas	area	nn2
currently	currently	rr
are	be	vbr
emerging	emerge	vvg_jj
:	:	y
the	the	at
role	role	nn1
of	of	io
deficits	deficit	nn2
in	in	ii
frontal	frontal	jj
cortex	cortex	nn1
functioning	function	vvg_nn1@
,	,	y
changes	change	nn2_vvz@
in	in	ii
the	the	at
brain	brain	nn1
neurocircuitry	neurocircuitry	nn1
that	that	cst
convey	convey	vv0
long-term	long-term	jj
vulnerability	vulnerability	nn1
to	to	to
relapse	relapse	vvi
,	,	y
and	and	cc
the	the	at
role	role	nn1
of	of	io
nondopaminergic	nondopaminergic	jj
systems	system	nn2
in	in	ii
the	the	at
neuroadaptations		nn2
associated	associate	vvn
with	with	iw
the	the	at
development	development	nn1
of	of	io
drug	drug	nn1
dependence	dependence	nn1
.	.	y
Parallel	parallel	rr_nn1_vv0@
to	to	ii
these	these	dd2
functional	functional	jj
changes	change	nn2
have	have	vh0
been	be	vbn
major	major	jj
advances	advance	nn2
in	in	ii
our	our	appge
understanding	understanding	nn1
of	of	io
the	the	at
molecular	molecular	jj
biology	biology	nn1
of	of	io
addiction	addiction	nn1
;	;	y
the	the	at
greatest	greatest	jjt
contribution	contribution	nn1
has	have	vhz
been	be	vbn
in	in	ii
the	the	at
understanding	understanding	nn1
of	of	io
the	the	at
molecular	molecular	jj
mechanisms	mechanism	nn2
of	of	io
opioid	opioid	jj_nn1
action	action	nn1
.	.	y
This	this	dd1
paper	paper	nn1
reviews	review	vvz
the	the	at
major	major	jj
developments	development	nn2
in	in	ii
our	our	appge
understanding	understanding	nn1
of	of	io
the	the	at
molecular	molecular	jj
biology	biology	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
to	to	to
advance	advance	vvi
our	our	appge
knowledge	knowledge	nn1
of	of	io
the	the	at
function	function	nn1
and	and	cc
regulation	regulation	nn1
of	of	io
opioid	opioid	jj_nn1
receptors	receptor	nn2
and	and	cc
endorphins	endorphin	nn2
.	.	y
<p>	<p>	y
A	a	at1
number	number	nn1
of	of	io
dramatic	dramatic	jj
breakthroughs	breakthrough	nn2
in	in	ii
the	the	at
neurobiology	neurobiology	nn1
of	of	io
addiction	addiction	nn1
have	have	vh0
occurred	occur	vvn
in	in	ii
the	the	at
past	past	jj
40	40	mc
years	year	nnt2
with	with	iw
the	the	at
support	support	nn1
of	of	io
the	the	at
National	national	jj
Institute	institute	nn1
on	on	ii
Drug	drug	nn1
Abuse	abuse	nn1
(	(	y
NIDA	nida	np1
)	)	y
.	.	y
Two	two	mc
domains	domain	nn2
will	will	vm
be	be	vbi
highlighted	highlight	vvn
here	here	rl
:	:	y
the	the	at
neurocircuitry	neurocircuitry	nn1
of	of	io
addiction	addiction	nn1
and	and	cc
the	the	at
molecular	molecular	jj
biology	biology	nn1
of	of	io
addiction	addiction	nn1
targets	target	nn2
.	.	y
Advances	advance	nn2_vvz
m	m	mc@_zz1
several	several	da2
areas	area	nn2
have	have	vh0
dominated	dominate	vvn
the	the	at
field	field	nn1
in	in	ii
the	the	at
neurocircuitry	neurocircuitry	nn1
of	of	io
addiction	addiction	nn1
.	.	y
Behaviorists	behaviorist	nn2_np1@
in	in	ii
the	the	at
United	united	np1
States	state	np1
laid	lay	vvd
the	the	at
groundwork	groundwork	nn1
for	for	if
the	the	at
development	development	nn1
of	of	io
the	the	at
animal	animal	nn1
models	model	nn2
of	of	io
addiction	addiction	nn1
.	.	y
The	the	at
neurobiological	neurobiological	jj
substrates	substrate	nn2
for	for	if
the	the	at
reinforcing	reinforcing	jj@
effects	effect	nn2
of	of	io
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
have	have	vh0
been	be	vbn
largely	largely	rr
identified	identify	vvn
both	both	rr
at	at	ii
the	the	at
initial	initial	jj_nn1
site	site	nn1
of	of	io
action	action	nn1
(	(	y
receptor	receptor	nn1
,	,	y
reuptake	reuptake	vv0_nn1
site	site	nn1
,	,	y
etc.	etc	ra
)	)	y
as	as	ii31
well	well	ii32
as	as	ii33
the	the	at
circuitry	circuitry	nn1
involved	involve	vvn_vvd
(	(	y
mesocorticolimbic	mesocorticolimbic	jj
dopamine	dopamine	nn1
system	system	nn1
and	and	cc
endogenous	endogenous	jj
opioid	opioid	jj_nn1
systems	system	nn2
)	)	y
.	.	y
In	in	ii
human	human	jj_nn1
imaging	imaging	nn1_vvg
studies	study	nn2
,	,	y
decreases	decrease	vvz
in	in	ii
dopaminergic	dopaminergic	jj
function	function	nn1
have	have	vh0
been	be	vbn
identified	identify	vvn
as	as	ii
a	a	at1
key	key	jj
common	common	jj
element	element	nn1
of	of	io
addiction	addiction	nn1
,	,	y
lending	lend	vvg_nn1
support	support	nn1_vv0
to	to	ii
what	what	ddq
became	become	vvd
a	a	at1
strong	strong	jj
program	program	nn1
on	on	ii
the	the	at
role	role	nn1
of	of	io
dopamine	dopamine	nn1
in	in	ii
addiction	addiction	nn1
(	(	y
Volkow	volkow	np1
&;		null
Fowler	fowler	np1
,	,	y
2000	2000	mc
)	)	y
.	.	y
<p>	<p>	y
However	however	rr
,	,	y
as	as	csa
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
emerging	emerge	vvg_jj
.	.	y
The	the	at
role	role	nn1
of	of	io
deficits	deficit	nn2
in	in	ii
frontal	frontal	jj
cortex	cortex	nn1
functioning	functioning	nn1@
has	have	vhz
become	become	vvn@
an	a	at1
area	area	nn1
of	of	io
intense	intense	jj
investigation	investigation	nn1
.	.	y
The	the	at
changes	change	nn2
in	in	ii
the	the	at
brain	brain	nn1
neurocircuitry	neurocircuitry	nn1
that	that	cst
convey	convey	vv0
long-term	long-term	jj
vulnerability	vulnerability	nn1
to	to	to
relapse	relapse	vvi
are	be	vbr
being	be	vbg
studied	study	vvn
.	.	y
The	the	at
role	role	nn1
of	of	io
nondopaminergic	nondopaminergic	jj
systems	system	nn2
in	in	ii
the	the	at
neuroadaptations		nn2
associated	associate	vvn
with	with	iw
the	the	at
development	development	nn1
of	of	io
drug	drug	nn1
dependence	dependence	nn1
has	have	vhz
also	also	rr
moved	move	vvn
to	to	ii
the	the	at
forefront	forefront	nn1
.	.	y
<p>	<p>	y
Parallel	parallel	rr_nn1_vv0@
to	to	ii
these	these	dd2
functional	functional	jj
changes	change	nn2
in	in	ii
the	the	at
neurobiology	neurobiology	nn1
of	of	io
addiction	addiction	nn1
have	have	vh0
been	be	vbn
major	major	jj
advances	advance	nn2
in	in	ii
our	our	appge
understanding	understanding	nn1
of	of	io
the	the	at
molecular	molecular	jj
biology	biology	nn1
of	of	io
addiction	addiction	nn1
.	.	y
Perhaps	perhaps	rr
one	one	mc1
of	of	io
the	the	at
greatest	greatest	jjt
contributions	contribution	nn2
has	have	vhz
been	be	vbn
in	in	ii
the	the	at
understanding	understanding	nn1
of	of	io
the	the	at
molecular	molecular	jj
mechanisms	mechanism	nn2
of	of	io
opioid	opioid	jj_nn1
action	action	nn1
.	.	y
Dr.	dr	nnb
Simon	simon	np1
's	's	ge
contribution	contribution	nn1
to	to	ii
these	these	dd2
reflections	reflection	nn2
will	will	vm
be	be	vbi
to	to	to
review	review	vvi
some	some	dd
of	of	io
the	the	at
major	major	jj
developments	development	nn2
(	(	y
"	"	y
breakthroughs	breakthrough	nn2
"	"	y
)	)	y
in	in	ii
our	our	appge
understanding	understanding	nn1
of	of	io
the	the	at
molecular	molecular	jj
biology	biology	nn1
and	and	cc
biochemistry	biochemistry	nn1
of	of	io
opiate	opiate	nn1
action	action	nn1
and	and	cc
the	the	at
endogenous	endogenous	jj
opioid	opioid	jj_nn1
system	system	nn1
.	.	y
Clearly	clearly	rr
,	,	y
the	the	at
list	list	nn1
of	of	io
breakthroughs	breakthrough	nn2
discussed	discuss	vvn
is	be	vbz
not	not	xx
exhaustive	exhaustive	jj
,	,	y
and	and	cc
the	the	at
topics	topic	nn2
chosen	choose	vvn
are	be	vbr
those	those	dd2
deemed	deem	vvn
most	most	dat_rgt
important	important	jj
by	by	ii
Dr.	dr	nnb
Simon	simon	np1
and	and	cc
within	within	ii
his	his	appge
areas	area	nn2
of	of	io
interest	interest	nn1
and	and	cc
expertise	expertise	nn1
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
CONCEPTUAL	conceptual	jj
FRAMEWORK	framework	nn1
FOR	for	if
ADDICTION	addiction	npx
Drug	drug	nn1
addiction	addiction	nn1
,	,	y
or	or	cc
substance	substance	nn1
dependence	dependence	nn1
,	,	y
is	be	vbz
a	a	at1
chronically	chronically	rr
relapsing	relapse	vvg_jj@
disorder	disorder	nn1
characterized	characterize	vvn
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
the	the	at
drug	drug	nn1
,	,	y
(	(	y
b	b	zz1
)	)	y
loss	loss	nn1
of	of	io
control	control	nn1
in	in	ii
limiting	limiting	jj_vvg
intake	intake	nn1
,	,	y
and	and	cc
(	(	y
c	c	zz1
)	)	y
emergence	emergence	nn1
of	of	io
a	a	at1
negative	negative	jj
emotional	emotional	jj
state	state	nn1
(	(	y
e.g.	eg	rex
,	,	y
dysphoria	dysphoria	nn1
,	,	y
anxiety	anxiety	nn1
,	,	y
irritability	irritability	nn1
)	)	y
when	when	rrq_cs
access	access	nn1
to	to	ii
the	the	at
drug	drug	nn1
is	be	vbz
prevented	prevent	vvn
.	.	y
Clinically	clinically	rr_np1@
,	,	y
the	the	at
occasional	occasional	jj
but	but	ccb
limited	limited	jj
use	use	nn1
of	of	io
an	a	at1
abusable	abusable	jj
drug	drug	nn1
is	be	vbz
distinct	distinct	jj
from	from	ii
escalated	escalated	jj%
drug	drug	nn1
use	use	nn1
and	and	cc
the	the	at
emergence	emergence	nn1
of	of	io
chronic	chronic	jj
drug	drug	nn1
dependence	dependence	nn1
.	.	y
An	a	at1
important	important	jj
goal	goal	nn1
of	of	io
current	current	jj
neurobiological	neurobiological	jj
research	research	nn1
is	be	vbz
to	to	to
understand	understand	vvi
the	the	at
neuropharmacological	neuropharmacological	jj
and	and	cc
neuroadaptive	neuroadaptive	jj
mechanisms	mechanism	nn2
within	within	ii
specific	specific	jj
neurocircuits		nn2
that	that	cst
mediate	mediate	vv0
the	the	at
transition	transition	nn1
from	from	ii
occasional	occasional	jj
,	,	y
controlled	control	vvd_jj@_vvn
drug	drug	nn1
use	use	nn1
and	and	cc
the	the	at
loss	loss	nn1
of	of	io
behavioral	behavioral	jj_nn1
control	control	nn1
over	over	ii
drug-seeking	drug-seeking	nn1_jj
,	,	y
and	and	cc
drug-taking	drug-taking	nn1
that	that	cst_dd1
defines	define	vvz
chronic	chronic	jj
addiction	addiction	nn1
.	.	y
Drug	drug	nn1
addiction	addiction	nn1
has	have	vhz
been	be	vbn
conceptualized	conceptualize	vvn@
as	as	ii
a	a	at1
disorder	disorder	nn1
that	that	cst_dd1
moves	move	vvz_nn2
from	from	ii
impulsivity	impulsivity	nn1
to	to	ii
compulsivity	compulsivity	nn1
in	in	ii
a	a	at1
collapsed	collapsed	jj%
cycle	cycle	nn1
of	of	io
addiction	addiction	nn1
comprised	comprise	vvn
of	of	io
three	three	mc
stages	stage	nn2
:	:	y
**26;5744;TOOLONG		fo
,	,	y
binge	binge	vv0_nn1
intoxication	intoxication	nn1
,	,	y
and	and	cc
withdrawal/		nn1
negative	negative	jj_nn1@
affect	affect	nn1
(	(	y
Figure	figure	nn1
1	1	mc1
;	;	y
Koob	koob	np1
,	,	y
2004	2004	mc
;	;	y
Koob	koob	np1
,	,	y
Sanna	sanna	np1
,	,	y
&;		null
Bloom	bloom	np1
,	,	y
1998	1998	mc
)	)	y
.	.	y
<p>	<p>	y
Multiple	multiple	jj_nn1
sources	source	nn2
of	of	io
reinforcement	reinforcement	nn1
can	can	vm
be	be	vbi
identified	identify	vvn
in	in	ii
these	these	dd2
three	three	mc
stages	stage	nn2
(	(	y
Koob	koob	np1
&;		null
Le	le	np1
Moal	moal	np1
,	,	y
2001	2001	mc
)	)	y
.	.	y
These	these	dd2
include	include	vv0
the	the	at
positive	positive	jj
reinforcement	reinforcement	nn1
of	of	io
the	the	at
binge	binge	nn1
intoxication	intoxication	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
a	a	at1
negative	negative	jj
emotional	emotional	jj
state	state	nn1
(	(	y
e.g.	eg	rex
,	,	y
dysphoria	dysphoria	nn1
,	,	y
anxiety	anxiety	nn1
,	,	y
and	and	cc
irritability	irritability	nn1
)	)	y
that	that	cst_dd1
emerges	emerge	vvz
when	when	rrq_cs
access	access	nn1
to	to	ii
the	the	at
drug	drug	nn1
is	be	vbz
prevented	prevent	vvn
during	during	ii
the	the	at
withdrawal/negative	withdrawal/negative	nn1
affect	affect	nn1_vv0
stage	stage	nn1
,	,	y
and	and	cc
the	the	at
conditioned	conditioned	jj
reinforcement	reinforcement	nn1
associated	associate	vvn
with	with	iw
the	the	at
**26;5772;TOOLONG		fo
(	(	y
craving	crave	vvg_nn1@
)	)	y
stage	stage	nn1
(	(	y
Koob	koob	np1
&;		null
Le	le	np1
Moal	moal	np1
,	,	y
2001	2001	mc
)	)	y
.	.	y
We	we	ppis2
will	will	vm
explore	explore	vvi
the	the	at
neurobiological	neurobiological	jj
mechanisms	mechanism	nn2
of	of	io
addiction	addiction	nn1
involved	involved	jj
in	in	ii
these	these	dd2
stages	stage	nn2
of	of	io
the	the	at
addiction	addiction	nn1
cycle	cycle	nn1
,	,	y
and	and	cc
how	how	rrq
research	research	nn1
has	have	vhz
progressed	progress	vvn
from	from	ii
a	a	at1
focus	focus	nn1
on	on	ii
the	the	at
neurochemical	neurochemical	jj
changes	change	nn2
associated	associate	vvn
with	with	iw
the	the	at
acute	acute	jj
reinforcing	reinforcing	jj@_vvg
effects	effect	nn2
of	of	io
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
to	to	ii
understanding	understand	vvg
the	the	at
neuroadaptative	neuroadaptative	jj
changes	change	nn2
that	that	cst
occur	occur	vv0
during	during	ii
the	the	at
transition	transition	nn1
from	from	ii
taking	take	vvg
drugs	drug	nn2
to	to	ii
addiction	addiction	nn1
.	.	y
A	a	at1_zz1
parallel	parallel	jj_nn1
evolution	evolution	nn1
has	have	vhz
been	be	vbn
the	the	at
exploration	exploration	nn1
of	of	io
first	first	md
the	the	at
neurocircuitry	neurocircuitry	nn1
changes	change	nn2
,	,	y
and	and	cc
then	then	rt
the	the	at
molecular	molecular	jj
changes	change	nn2
,	,	y
responsible	responsible	jj
for	for	if
the	the	at
neuroadaptations		nn2
that	that	cst
mediate	mediate	vv0
the	the	at
development	development	nn1
of	of	io
addiction	addiction	nn1
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
ANIMAL	animal	nn1
MODELS	model	nn2
OF	of	io
DRUG	drug	nn1
ABUSE	abuse	nn1
AND	and	cc
DEPENDENCE	dependence	nn1
Much	much	da1_rr
of	of	io
the	the	at
recent	recent	jj
progress	progress	nn1
in	in	ii
understanding	understand	vvg
the	the	at
mechanisms	mechanism	nn2
of	of	io
addiction	addiction	nn1
has	have	vhz
derived	derive	vvn
from	from	ii
the	the	at
study	study	nn1
of	of	io
animal	animal	nn1
models	model	nn2
of	of	io
addiction	addiction	nn1
on	on	ii
specific	specific	jj
drugs	drug	nn2
such	such	ii21
as	as	ii22
opiates	opiate	nn2
,	,	y
stimulants	stimulant	nn2
,	,	y
and	and	cc
alcohol	alcohol	nn1
(	(	y
Shippenberg		np1
&;		null
Koob	koob	np1
,	,	y
2002	2002	mc
)	)	y
.	.	y
While	while	cs
no	no	at
animal	animal	nn1
model	model	nn1
of	of	io
addiction	addiction	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
investigation	investigation	nn1
of	of	io
specific	specific	jj
elements	element	nn2
of	of	io
the	the	at
process	process	nn1
of	of	io
drug	drug	nn1
addiction	addiction	nn1
.	.	y
Such	such	da
elements	element	nn2
can	can	vm
be	be	vbi
defined	define	vvn
by	by	ii
models	model	nn2
of	of	io
different	different	jj
systems	system	nn2
,	,	y
models	model	nn2
of	of	io
psychological	psychological	jj
constructs	construct	nn2
,	,	y
such	such	ii21
as	as	ii22
positive	positive	jj
and	and	cc
negative	negative	jj
reinforcement	reinforcement	nn1
,	,	y
and	and	cc
models	model	nn2
of	of	io
different	different	jj
stages	stage	nn2
of	of	io
the	the	at
addiction	addiction	nn1
cycle	cycle	nn1
Initially	initially	rr
,	,	y
animal	animal	nn1
models	model	nn2
of	of	io
addiction	addiction	nn1
focused	focus	vvn_vvd
on	on	ii
the	the	at
synaptic	synaptic	jj
sites	site	nn2
and	and	cc
transductive	transductive	jj
mechanisms	mechanism	nn2
(	(	y
how	how	rrq
these	these	dd2
sites	site	nn2
convey	convey	vv0
changes	change	nn2
m	m	zz1
excitability	excitability	nn1
)	)	y
m	m	zz1_mc@
the	the	at
nervous	nervous	jj
system	system	nn1
on	on	ii
which	which	ddq
drugs	drug	nn2
act	act	vv0
initially	initially	rr
to	to	to
produce	produce	vvi
their	their	appge
positive	positive	jj
reinforcing	reinforcing	jj@_vvg
effects	effect	nn2
.	.	y
Well-validated	well-validated	jj
animal	animal	nn1
models	model	nn2
exist	exist	vv0
for	for	if
the	the	at
positive	positive	jj
reinforcing	reinforcing	jj@_vvg
effects	effect	nn2
of	of	io
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
with	with	iw
high	high	jj
predictive	predictive	jj
validity	validity	nn1
.	.	y
Drugs	drug	nn2
self-administered	self-administered	nn1_jj
by	by	ii
animals	animal	nn2
correspond	correspond	vv0
well	well	rr
with	with	iw
those	those	dd2
with	with	iw
high	high	jj
abuse	abuse	nn1
potential	potential	nn1
in	in	ii
humans	human	nn2
,	,	y
and	and	cc
intravenous	intravenous	jj
drug	drug	nn1
self-administration	self-administration	nn1
is	be	vbz
considered	consider	vvn
an	a	at1
animal	animal	nn1
model	model	nn1
predictive	predictive	jj
of	of	io
abuse	abuse	nn1
potential	potential	nn1
.	.	y
Other	other	jj
validated	validated	jj@
measures	measure	nn2
of	of	io
the	the	at
acute	acute	jj
rewarding	rewarding	jj
effects	effect	nn2
of	of	io
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
:	:	y
include	include	vv0
brain	brain	nn1
stimulation	stimulation	nn1
reward	reward	nn1
and	and	cc
conditioned	conditioned	jj
place	place	nn1
preference	preference	nn1
.	.	y
<p>	<p>	y
Animal	animal	nn1
models	model	nn2
of	of	io
components	component	nn2
of	of	io
the	the	at
negative	negative	jj_nn1@
reinforcing	reinforcing	jj@_vvg
effects	effect	nn2
of	of	io
dependence	dependence	nn1
have	have	vh0
subsequently	subsequently	rr
been	be	vbn
developed	develop	vvn
,	,	y
and	and	cc
animal	animal	nn1
models	model	nn2
of	of	io
craving	crave	vvg_nn1@
are	be	vbr
being	be	vbg
used	use	vvn
to	to	to
explore	explore	vvi
how	how	rrq
the	the	at
nervous	nervous	jj
system	system	nn1
adapts	adapt	vvz
to	to	ii
drug	drug	nn1
use	use	nn1
.	.	y
Measures	measure	nn2
of	of	io
the	the	at
negative	negative	jj
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
access	access	nn1
to	to	ii
the	the	at
drug	drug	nn1
is	be	vbz
provided	provide	vvn
or	or	cc
the	the	at
animals	animal	nn2
are	be	vbr
made	make	vvn
dependent	dependent	jj_nn1@
with	with	iw
chronic	chronic	jj
exposure	exposure	nn1
.	.	y
Dependent	dependent	jj
animals	animal	nn2
increase	increase	vv0
the	the	at
amount	amount	nn1
of	of	io
drug	drug	nn1
self-administration	self-administration	nn1
,	,	y
increase	increase	vv0
the	the	at
motivation	motivation	nn1
to	to	to
take	take	vvi
drugs	drug	nn2
,	,	y
and	and	cc
show	show	vvi
an	a	at1
increase	increase	nn1
in	in	ii
drug	drug	nn1
seeking	seek	vvg_nn1@
.	.	y
These	these	dd2
models	model	nn2
provide	provide	vv0
validity	validity	nn1
model	model	nn1
for	for	if
compulsive	compulsive	jj
drug	drug	nn1
use	use	vv0_nn1
that	that	cst_dd1
characterizes	characterize	vvz
the	the	at
withdrawal/negative	withdrawal/negative	nn1
affect	affect	nn1_vv0
stage	stage	nn1
of	of	io
the	the	at
addiction	addiction	nn1
cycle	cycle	nn1
and	and	cc
the	the	at
transition	transition	nn1
to	to	ii
addiction	addiction	nn1
.	.	y
Other	other	jj
measures	measure	nn2
of	of	io
the	the	at
withdrawal/negative	withdrawal/negative	nn1
affect	affect	nn1_vv0
stage	stage	nn1
include	include	vv0
anxiety-like	anxiety-like	jj
decreases	decrease	nn2@_vvz
in	in	ii
reward	reward	nn1
as	as	csa
measured	measure	vvn
by	by	ii
increases	increase	nn2
in	in	ii
threshold	threshold	nn1
for	for	if
brain	brain	nn1
stimulation	stimulation	nn1
reward	reward	nn1
and	and	cc
place	place	vv0_nn1
aversions	aversion	nn2
to	to	ii
a	a	at1
withdrawal	withdrawal	nn1
stimulus	stimulus	nn1
.	.	y
Increases	increase	nn2_vvz
in	in	ii
brain	brain	nn1
reward	reward	nn1
thresholds	threshold	nn2
have	have	vh0
been	be	vbn
observed	observe	vvn
following	following	ii@_vvg_jj@
withdrawal	withdrawal	nn1
from	from	ii
psychomotor	psychomotor	nn1
stimulants	stimulant	nn2
,	,	y
opiates	opiate	nn2_vvz
,	,	y
ethanol	ethanol	nn1
,	,	y
D9-tetrahydrocannabinol	d9-tetrahydrocannabinol	nn1_jj
(	(	y
THC	thc	np1
)	)	y
.	.	y
<p>	<p>	y
Human	human	jj_nn1
studies	study	nn2
have	have	vh0
shown	show	vvn
that	that	cst
the	the	at
presentation	presentation	nn1
of	of	io
drugs	drug	nn2
themselves	themselves	ppx2
,	,	y
or	or	cc
stimuli	stimulus	nn2
previously	previously	rr
associated	associate	vvn
with	with	iw
drug	drug	nn1
delivery	delivery	nn1
or	or	cc
drug	drug	nn1
withdrawal	withdrawal	nn1
,	,	y
or	or	cc
the	the	at
state	state	nn1
Of	of	io
stress	stress	nn1
,	,	y
increase	increase	vv0
the	the	at
likelihood	likelihood	nn1
of	of	io
relapse	relapse	nn1
as	as	ii31
well	well	ii32
as	as	ii33
self-reports	self-report	nn2
of	of	io
craving	crave	vvg_nn1@_jj@
and	and	cc
motivation	motivation	nn1
to	to	to
engage	engage	vvi
in	in	ii
drug-taking	drug-taking	nn1
.	.	y
Animal	animal	nn1
models	model	nn2
have	have	vh0
been	be	vbn
developed	develop	vvn
that	that	cst
reflect	reflect	vv0
all	all	db
three	three	mc
stimuli	stimulus	nn2
important	important	jj
for	for	if
relapse	relapse	nn1
:	:	y
ingestion	ingestion	nn1
of	of	io
the	the	at
drug	drug	nn1
itself	itself	ppx1
,	,	y
cues	cue	nn2
associated	associate	vvn
with	with	iw
the	the	at
drug	drug	nn1
,	,	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
of	of	io
craving	crave	vvg_nn1@
can	can	vm
be	be	vbi
divided	divide	vvn
into	into	ii
two	two	mc
domains	domain	nn2
:	:	y
drug-seeking	drug-seeking	nn1_jj
induced	induce	vvn
by	by	ii
stimuli	stimulus	nn2
paired	pair	vvn_vvd
with	with	iw
drug-taking	drug-taking	nn1
,	,	y
and	and	cc
drug-seeking	drug-seeking	nn1_jj
induced	induce	vvn
by	by	ii
an	a	at1
acute	acute	jj
stressor	stressor	nn1
or	or	cc
a	a	at1
state	state	nn1
of	of	io
stress	stress	nn1
.	.	y
Drug-seeking	drug-seeking	nn1
can	can	vm
be	be	vbi
reinstated	reinstate	vvn
in	in	ii
animals	animal	nn2
that	that	cst
have	have	vh0
acquired	acquire	vvn
drug	drug	nn1
self-administration	self-administration	nn1
and	and	cc
then	then	rt
have	have	vh0
been	be	vbn
subjected	subject	vvn
to	to	ii
extinction	extinction	nn1
of	of	io
responding	respond	vvg
for	for	if
the	the	at
drug	drug	nn1
by	by	ii
the	the	at
use	use	nn1
of	of	io
drug	drug	nn1
stimuli	stimulus	nn2
,	,	y
cues	cue	nn2
paired	pair	vvn_vvd
with	with	iw
or	or	cc
predicting	predict	vvg
drug	drug	nn1
taking	take	vvg
,	,	y
and	and	cc
stress	stress	nn1_vv0@
induction	induction	nn1
(	(	y
McFarland	mcfarland	np1
&;		null
Kalivas	kalivas	np2
,	,	y
2001	2001	mc
;	;	y
Shaham	shaham	np1
,	,	y
Shalev	shalev	np1
,	,	y
Lu	lu	np1_nn1
,	,	y
De	de	np1
Wit	wit	nn1
,	,	y
&;		null
Stewart	stewart	np1
,	,	y
2003	2003	mc
)	)	y
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
NEUROCIRCUITRY	neurocircuitry	nn1_np1
OF	of	io
DRUG	drug	nn1
REWARD	reward	nn1
AND	and	cc
ANTI-REWARD	anti-reward	jj
RELEVANT	relevant	jj
TO	to	ii
ADDICTION	addiction	npx
A	a	zz1
key	key	jj
element	element	nn1
of	of	io
drug	drug	nn1
addiction	addiction	nn1
is	be	vbz
how	how	rrq
the	the	at
brain	brain	nn1
reward	reward	nn1
system	system	nn1
changes	change	nn2_vvz@
with	with	iw
the	the	at
development	development	nn1
of	of	io
addiction	addiction	nn1
,	,	y
and	and	cc
one	one	pn1
must	must	vm
understand	understand	vvi
the	the	at
neurobiological	neurobiological	jj
bases	base	nn2
for	for	if
acute	acute	jj
drug	drug	nn1
reward	reward	nn1
to	to	to
understand	understand	vvi
how	how	rrq
these	these	dd2
systems	system	nn2
change	change	vv0
as	as	csa_ii@
addiction	addiction	nn1
develops	develop	vvz
.	.	y
A	a	at1
principle	principle	nn1
focus	focus	nn1
of	of	io
research	research	nn1
on	on	ii
the	the	at
neurobiology	neurobiology	nn1
of	of	io
the	the	at
positive	positive	jj
reinforcing	reinforcing	jj@_vvg
effects	effect	nn2
of	of	io
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
has	have	vhz
been	be	vbn
the	the	at
origins	origin	nn2
and	and	cc
terminal	terminal	jj_nn1
areas	area	nn2
of	of	io
the	the	at
mesocorticolimbic	mesocorticolimbic	jj
dopamine	dopamine	nn1
system	system	nn1
,	,	y
and	and	cc
evidence	evidence	nn1
for	for	if
the	the	at
importance	importance	nn1
of	of	io
this	this	dd1
system	system	nn1
in	in	ii
psychostimulant	psychostimulant	jj_nn1
reward	reward	nn1
is	be	vbz
compelling	compelling	jj_vvg
(	(	y
Koob	koob	np1
,	,	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
to	to	to
include	include	vvi
other	other	jj
drugs	drug	nn2
,	,	y
as	as	ii31
well	well	ii32
as	as	ii33
the	the	at
many	many	da2
neural	neural	jj
inputs	input	nn2
and	and	cc
outputs	output	vvz_nn2
that	that	cst
interact	interact	vv0
with	with	iw
the	the	at
dopamine	dopamine	nn1
projection	projection	nn1
from	from	ii
the	the	at
ventral	ventral	jj
tegmental	tegmental	jj
area	area	nn1
to	to	ii
the	the	at
basal	basal	jj
forebrain	forebrain	nn1
and	and	cc
includes	include	vvz
dopamine-independent	dopamine-independent	jj
components	component	nn2
of	of	io
drug	drug	nn1
reward	reward	nn1
(	(	y
Figure	figure	nn1
2	2	mc
)	)	y
.	.	y
<p>	<p>	y
In	in	ii31
addition	addition	ii32
to	to	ii33
the	the	at
mesocorticolimbic	mesocorticolimbic	jj
dopamine	dopamine	nn1
system	system	nn1
and	and	cc
its	its	z'
projections	projection	nn2
,	,	y
specific	specific	jj
components	component	nn2
of	of	io
the	the	at
basal	basal	jj
forebrain	forebrain	nn1
have	have	vh0
more	more	rgr
recently	recently	rr
been	be	vbn
identified	identify	vvn
with	with	iw
the	the	at
hedonic	hedonic	jj
neuroadaptations		nn2
to	to	ii
acute	acute	jj
drug	drug	nn1
reward	reward	nn1
and	and	cc
have	have	vh0
focused	focus	vvn
on	on	ii
elements	element	nn2
of	of	io
the	the	at
extended	extended	jj@
amygdala	amygdala	nn1
(	(	y
Koob	koob	np1
,	,	y
2003	2003	mc
)	)	y
.	.	y
As	as	ii_csa
the	the	at
neural	neural	jj_nn1
circuits	circuit	nn2
for	for	if
the	the	at
reinforcing	reinforcing	jj@
effects	effect	nn2
of	of	io
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
have	have	vh0
evolved	evolve	vvn
,	,	y
the	the	at
role	role	nn1
of	of	io
neurotransmitters/		fu
neuromodulators	neuromodulators	nn2
also	also	rr
have	have	vh0
evolved	evolve	vvn
,	,	y
and	and	cc
four	four	mc
of	of	io
those	those	dd2
systems	system	nn2
are	be	vbr
discussed	discuss	vvn
below	below	rl
;	;	y
mesolimbic	mesolimbic	jj
dopamine	dopamine	nn1
,	,	y
opioid	opioid	jj_nn1
peptide	peptide	nn1
,	,	y
gamma-aminobutyric	gamma-aminobutyric	jj
acid	acid	nn1
(	(	y
GABA	gaba	np1
)	)	y
,	,	y
and	and	cc
serotonin	serotonin	nn1
(	(	y
Table	table	nn1
1	1	mc1
)	)	y
.	.	y
Significant	significant	jj
evidence	evidence	nn1
exists	exist	vvz
for	for	if
both	both	rr
dopamine-dependent	dopamine-dependent	jj
and	and	cc
-independent	-independent	jj
neurocircuitry	neurocircuitry	nn1
in	in	ii
drug	drug	nn1
reward	reward	nn1
with	with	iw
a	a	at1
focus	focus	nn1
on	on	ii
the	the	at
nucleus	nucleus	nn1
accumbens	accumbens	nn2
and	and	cc
amygdala	amygdala	nn1
(	(	y
Koob	koob	np1
,	,	y
1992	1992	mc
)	)	y
.	.	y
<p>	<p>	y
All	all	db_rr@
major	major	jj
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
produce	produce	vv0_nn1@
dysphoria	dysphoria	nn1
during	during	ii
withdrawal	withdrawal	nn1
,	,	y
and	and	cc
animal	animal	nn1
models	model	nn2
show	show	vv0
an	a	at1
elevation	elevation	nn1
of	of	io
reward	reward	nn1
thresholds	threshold	nn2
as	as	csa
measured	measure	vvn
by	by	ii
brain	brain	nn1
stimulation	stimulation	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
cocaine	cocaine	nn1
,	,	y
opiates	opiate	nn2
'	'	ge
,	,	y
alcohol	alcohol	nn1
,	,	y
nicotine	nicotine	nn1
,	,	y
and	and	cc
THC	thc	np1
A	a	zz1
logical	logical	jj
explanation	explanation	nn1
for	for	if
the	the	at
neuroadaptative	neuroadaptative	jj
mechanisms	mechanism	nn2
responsible	responsible	jj
for	for	if
the	the	at
negative	negative	jj
motivational	motivational	jj
effects	effect	nn2
of	of	io
drug	drug	nn1
withdrawal	withdrawal	nn1
(	(	y
the	the	at
"	"	y
dark	dark	jj_nn1
side	side	nn1
)	)	y
may	may	vm
involve	involve	vvi
disruption	disruption	nn1
of	of	io
the	the	at
same	same	da
neural	neural	jj_nn1
systems	system	nn2
implicated	implicate	vvd_vvn@
in	in	ii
the	the	at
positive	positive	jj
reinforcing	reinforcing	jj@_vvg
effects	effect	nn2
of	of	io
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
(	(	y
Table	table	nn1
1	1	mc1
)	)	y
(	(	y
Koob	koob	np1
&;		null
Le	le	np1
Moal	moal	np1
,	,	y
2005	2005	mc
)	)	y
.	.	y
<p>	<p>	y
As	as	ii
such	such	da
,	,	y
these	these	dd2
effects	effect	nn2
may	may	vm
reflect	reflect	vvi
changes	change	nn2
in	in	ii
the	the	at
activity	activity	nn1
of	of	io
reward	reward	nn1
neurotransmitter	neurotransmitter	nn1_vv0
systems	system	nn2
in	in	ii
the	the	at
midbrain	midbrain	nn1
and	and	cc
forebrain	forebrain	nn1
implicated	implicate	vvd_vvn@
in	in	ii
the	the	at
positive	positive	jj
reinforcing	reinforcing	jj@_vvg
effects	effect	nn2
of	of	io
drugs	drug	nn2
.	.	y
Examples	example	nn2
of	of	io
such	such	da
changes	change	nn2
at	at	ii
the	the	at
neurochemical	neurochemical	jj
level	level	nn1
include	include	vv0
decreases	decrease	nn2@_vvz
in	in	ii
dopaminergic	dopaminergic	jj
and	and	cc
serotonergic	serotonergic	jj
transmission	transmission	nn1
in	in	ii
the	the	at
nucleus	nucleus	nn1
accumbens	accumbens	nn2
during	during	ii
drug	drug	nn1
withdrawal	withdrawal	nn1
as	as	csa
measured	measure	vvn
by	by	ii
in	in	jj21
vivo	vivo	jj22
microdialysis	microdialysis	nn1
,	,	y
increased	increased	jj_vvd
sensitivity	sensitivity	nn1
of	of	io
opioid	opioid	jj_nn1
receptor	receptor	nn1
transduction	transduction	nn1
mechanisms	mechanism	nn2
in	in	ii
the	the	at
nucleus	nucleus	nn1
accumbens	accumbens	nn2
during	during	ii
opiate	opiate	nn1
withdrawal	withdrawal	nn1
,	,	y
decreased	decrease	vvd_vvn
GABAergic	gabaergic	jj
and	and	cc
increased	increase	vvd_jj
N-methyl-D-aspartate	n-methyl-d-aspartate	np1
(	(	y
NMDA	nmda	np1
)	)	y
glutamatergic	glutamatergic	jj
transmission	transmission	nn1
during	during	ii
alcohol	alcohol	nn1
withdrawal	withdrawal	nn1
,	,	y
and	and	cc
differential	differential	jj
regional	regional	jj
changes	change	nn2
in	in	ii
nicotinic	nicotinic	jj
receptor	receptor	nn1
function	function	nn1
.	.	y
The	the	at
decreases	decrease	nn2@
in	in	ii
reward	reward	nn1
neurotransmitters	neurotransmitter	nn2
have	have	vh0
been	be	vbn
hypothesized	hypothesize	vvn@
to	to	to
contribute	contribute	vvi
significantly	significantly	rr
to	to	ii
the	the	at
negative	negative	jj
motivational	motivational	jj
state	state	nn1
associated	associate	vvn
with	with	iw
acute	acute	jj
drug	drug	nn1
abstinence	abstinence	nn1
and	and	cc
may	may	vm
trigger	trigger	vvi
long-term	long-term	jj
biochemical	biochemical	jj
changes	change	nn2
that	that	cst
contribute	contribute	vv0
to	to	ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
(	(	y
Koob	koob	np1
&;		null
Le	le	np1
Moal	moal	np1
,	,	y
2001	2001	mc
)	)	y
.	.	y
<p>	<p>	y
However	however	rr
,	,	y
different	different	jj
neurochemical	neurochemical	jj
systems	system	nn2
involved	involved	jj
in	in	ii
stress	stress	nn1
modulation	modulation	nn1
also	also	rr
may	may	vm
be	be	vbi
engaged	engage	vvn
within	within	ii
the	the	at
neurocircuitry	neurocircuitry	nn1
of	of	io
the	the	at
brain	brain	nn1
reward	reward	nn1
and	and	cc
stress	stress	nn1_vv0@
systems	system	nn2
in	in	ii
an	a	at1
attempt	attempt	nn1
to	to	to
overcome	overcome	vvi
the	the	at
chronic	chronic	jj
presence	presence	nn1
of	of	io
the	the	at
drug	drug	nn1
and	and	cc
to	to	to
restore	restore	vvi
normal	normal	jj
function	function	nn1
despite	despite	ii
its	its	z'
presence	presence	nn1
.	.	y
Chronic	chronic	jj
administration	administration	nn1
of	of	io
drugs	drug	nn2
with	with	iw
dependence	dependence	nn1
potential	potential	nn1
also	also	rr
dysregulate	dysregulate	vv0
both	both	rr
the	the	at
**30;5800;TOOLONG		jj
(	(	y
HPA	hpa	np1
)	)	y
axis	axis	nn1
and	and	cc
the	the	at
brain	brain	nn1
stress	stress	nn1
system	system	nn1
mediated	mediate	vvd_vvn@
by	by	ii
corticotropin-releasing	corticotropin-releasing	jj_nn1
factor	factor	nn1
(	(	y
CRF	crf	np1
)	)	y
(	(	y
Heinrichs	heinrich	np2_vvz@
&;		null
Koob	koob	np1_vv0@
,	,	y
2004	2004	mc
)	)	y
.	.	y
CRF	crf	np1
is	be	vbz
a	a	at1
41	41	mc
amino	amino	nn1
acid	acid	nn1
polypeptide	polypeptide	nn1
with	with	iw
a	a	at1
wide	wide	jj
distribution	distribution	nn1
throughout	throughout	ii
the	the	at
brain	brain	nn1
but	but	ccb
with	with	iw
high	high	jj
concentrations	concentration	nn2
of	of	io
cell	cell	nn1
bodies	body	nn2
in	in	ii
the	the	at
paraventricular	paraventricular	jj
nucleus	nucleus	nn1
of	of	io
the	the	at
hypothalamus	hypothalamus	nn1
,	,	y
the	the	at
basal	basal	jj
forebrain	forebrain	nn1
,	,	y
and	and	cc
notably	notably	rr
the	the	at
extended	extended	jj@
amygdala	amygdala	nn1
and	and	cc
brainstem	brainstem	nn1_vv0
.	.	y
Central	central	jj
administration	administration	nn1
of	of	io
CRF	crf	np1
mimics	mimic	vvz
the	the	at
behavioral	behavioral	jj_nn1
response	response	nn1
to	to	ii
activation	activation	nn1
and	and	cc
stress	stress	nn1_vv0@
in	in	ii
rodents	rodent	nn2
.	.	y
Administration	administration	nn1
of	of	io
competitive	competitive	jj
CRF	crf	np1
receptor	receptor	nn1
antagonists	antagonist	nn2
generally	generally	rr
has	have	vhz
the	the	at
opposite	opposite	jj
effects	effect	nn2
.	.	y
Common	common	jj
responses	response	nn2
include	include	vv0
an	a	at1
activated	activated	jj@
HPA	hpa	nn1
stress	stress	nn1
response	response	nn1
,	,	y
elevated	elevate	vvd_jj_vvn
adrenocorticotropic	adrenocorticotropic	jj
hormone	hormone	nn1
and	and	cc
corticosteroids	corticosteroid	nn2
,	,	y
and	and	cc
an	a	at1
activated	activated	jj@
brain	brain	nn1
stress	stress	nn1
response	response	nn1
with	with	iw
activated	activated	jj@
amygdala	amygdala	nn1
CRF	crf	np1
during	during	ii
acute	acute	jj
withdrawal	withdrawal	nn1
from	from	ii
all	all	db
major	major	jj
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
in	in	ii
drug-seeking	drug-seeking	nn1
observed	observe	vvn_vvd
in	in	ii
extended	extended	jj@
access	access	nn1
and	and	cc
dependence	dependence	nn1
(	(	y
Koob	koob	np1
,	,	y
2008	2008	mc
)	)	y
.	.	y
<p>	<p>	y
Acute	acute	jj
withdrawal	withdrawal	nn1
from	from	ii
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
also	also	rr
may	may	vm
increase	increase	vvi
the	the	at
release	release	nn1
of	of	io
norepinephrine	norepinephrine	nn1_jj
in	in	ii
the	the	at
bed	bed	nn1
nucleus	nucleus	nn1
of	of	io
the	the	at
stria	stria	nn1
terminalis	terminalis	nn1
(	(	y
BNST		np1
)	)	y
and	and	cc
decrease	decrease	vv0_nn1
levels	level	nn2
of	of	io
neuropeptide	neuropeptide	nn1
Y	y	zz1
(	(	y
NPY	npy	np1
)	)	y
in	in	ii
the	the	at
central	central	jj
and	and	cc
medial	medial	jj
nuclei	nucleus	nn2
of	of	io
the	the	at
amygdala	amygdala	nn1
(	(	y
Heilig	heilig	np1_vv0_nn1
,	,	y
Koob	koob	np1
,	,	y
Ekman	ekman	np1_nn1
,	,	y
&;		null
Britton	britton	np1
,	,	y
1994	1994	mc
;	;	y
Koob	koob	np1
&;		null
Le	le	np1
Moal	moal	np1
,	,	y
2005	2005	mc
)	)	y
.	.	y
<p>	<p>	y
These	these	dd2
results	result	nn2
suggest	suggest	vv0
not	not	xx
only	only	rr
a	a	at1
change	change	nn1
in	in	ii
function	function	nn1
of	of	io
neurotransmitters	neurotransmitter	nn2
associated	associate	vvn
with	with	iw
the	the	at
acute	acute	jj
reinforcing	reinforcing	jj@_vvg
effects	effect	nn2
of	of	io
drugs	drug	nn2
(	(	y
dopamine	dopamine	vv0_nn1
,	,	y
opioid	opioid	jj_nn1
peptides	peptide	nn2
,	,	y
serotonin	serotonin	nn1
,	,	y
and	and	cc
GABA	gaba	np1_nn1
)	)	y
during	during	ii
the	the	at
development	development	nn1
of	of	io
dependence	dependence	nn1
,	,	y
but	but	ccb
also	also	rr
recruitment	recruitment	nn1
of	of	io
the	the	at
brain	brain	nn1
arousal	arousal	nn1
and	and	cc
stress	stress	nn1_vv0@
systems	system	nn2
(	(	y
glutamate	glutamate	nn1
,	,	y
CRF	crf	np1
,	,	y
and	and	cc
norepinephrine	norepinephrine	nn1_jj
)	)	y
and	and	cc
dysregulation	dysregulation	nn1
of	of	io
the	the	at
NPY	npy	jj_nn1
brain	brain	nn1
anti-stress	anti-stress	nn1_jj
system	system	nn1
.	.	y
These	these	dd2
changes	change	nn2
would	would	vm
represent	represent	vvi
a	a	at1
"	"	y
between-system	between-system	jj_nn1
"	"	y
neuroadaptation	neuroadaptation	nn1
.	.	y
Reward	reward	nn1_vv0@
mechanisms	mechanism	nn2
in	in	ii
dependence	dependence	nn1
are	be	vbr
compromised	compromise	vvn
by	by	ii
disruption	disruption	nn1
of	of	io
neurochemical	neurochemical	jj
systems	system	nn2
involved	involved	jj
in	in	ii
processing	process	vvg
natural	natural	jj
rewards	reward	nn2
and	and	cc
by	by	ii
recruitment	recruitment	nn1
of	of	io
the	the	at
anti-reward	anti-reward	jj_nn1
systems	system	nn2
that	that	cst
represent	represent	vv0
neuroadaptation	neuroadaptation	nn1
to	to	ii
the	the	at
chronic	chronic	jj
exposure	exposure	nn1
of	of	io
the	the	at
brain	brain	nn1
reward	reward	nn1
neurocircuitry	neurocircuitry	nn1
to	to	ii
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
(	(	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
neuroanatomical	neuroanatomical	jj
entity	entity	nn1
termed	term	vvd_vvn
the	the	at
extended	extended	jj@
amygdala	amygdala	nn1
thus	thus	rr
may	may	vm
represent	represent	vvi
a	a	at1
common	common	jj
anatomical	anatomical	jj
substrate	substrate	nn1
for	for	if
some	some	dd
aspects	aspect	nn2
of	of	io
acute	acute	jj
drug	drug	nn1
reward	reward	nn1
and	and	cc
a	a	at1
common	common	jj
neuroanatomical	neuroanatomical	jj
substrate	substrate	nn1
for	for	if
the	the	at
negative	negative	jj
effects	effect	nn2
on	on	ii
reward	reward	nn1
function	function	nn1
produced	produce	vvn
by	by	ii
stress	stress	nn1
that	that	cst_dd1
help	help	vv0_nn1
drive	drive	vvi
compulsive	compulsive	jj
drug	drug	nn1
administration	administration	nn1
.	.	y
The	the	at
extended	extended	jj@
amygdala	amygdala	nn1
receives	receive	vvz
numerous	numerous	jj
afferents	afferent	nn2
from	from	ii
limbic	limbic	jj
structures	structure	nn2
,	,	y
such	such	ii21
as	as	ii22
the	the	at
basolateral	basolateral	jj_nn1
amygdala	amygdala	nn1
and	and	cc
hippocampus	hippocampus	nn1
,	,	y
and	and	cc
sends	send	vvz
efferents	efferents	nn2
to	to	ii
the	the	at
medial	medial	jj
part	part	nn1
of	of	io
the	the	at
ventral	ventral	jj
pallidum	pallidum	nn1
and	and	cc
a	a	at1
large	large	jj
projection	projection	nn1
to	to	ii
the	the	at
lateral	lateral	jj
hypothalamus	hypothalamus	nn1
,	,	y
further	far	rrr
defining	define	vvg
the	the	at
specific	specific	jj
brain	brain	nn1
areas	area	nn2
that	that	cst
interface	interface	vv0
classical	classical	jj
limbic	limbic	jj
(	(	y
emotional	emotional	jj
)	)	y
structures	structure	nn2_vvz@
with	with	iw
the	the	at
extrapyramidal	extrapyramidal	jj
motor	motor	nn1
system	system	nn1
(	(	y
Koob	koob	np1
,	,	y
2003	2003	mc
)	)	y
.	.	y
<p>	<p>	y
Animal	animal	nn1
models	model	nn2
of	of	io
"	"	y
craving	crave	vvg_nn1@
"	"	y
involve	involve	vv0
the	the	at
use	use	nn1
of	of	io
drug-primed	drug-primed	jj_nn1
reinstatement	reinstatement	nn1
,	,	y
cue-induced	cue-induced	jj_nn1
reinstatement	reinstatement	nn1
,	,	y
or	or	cc
stress-induced	stress-induced	jj_nn1
reinstatement	reinstatement	nn1
in	in	ii
animals	animal	nn2
that	that	cst
acquire	acquire	vv0
drug	drug	nn1
self-administration	self-administration	nn1
and	and	cc
then	then	rt
are	be	vbr
subjected	subject	vvn
to	to	ii
extinction	extinction	nn1
of	of	io
responding	respond	vvg
for	for	if
the	the	at
drug	drug	nn1
.	.	y
Most	most	dat
evidence	evidence	nn1
from	from	ii
animal	animal	nn1
studies	study	nn2
suggests	suggest	vvz
that	that	cst_dd1
drug-induced	drug-induced	jj_nn1
reinstatement	reinstatement	nn1
is	be	vbz
localized	localize	vvn@_jj
to	to	ii
a	a	at1
medial	medial	jj
prefrontal	prefrontal	jj
cortex/nucleus	cortex/nucleus	nn1
accumbens/ventral		fu
pallidum	pallidum	nn1
circuit	circuit	nn1
mediated	mediate	vvd_vvn@
by	by	ii
the	the	at
neurotransmitter	neurotransmitter	nn1
glutamate	glutamate	nn1
.	.	y
In	in	ii
contrast	contrast	nn1
,	,	y
neuropharmacological	neuropharmacological	jj
and	and	cc
neurobiological	neurobiological	jj
studies	study	nn2
using	use	vvg
animal	animal	nn1
models	model	nn2
for	for	if
cue-induced	cue-induced	jj_nn1
reinstatement	reinstatement	nn1
involve	involve	vv0
the	the	at
basolateral	basolateral	jj_nn1
amygdala	amygdala	nn1
as	as	ii_csa
a	a	at1
critical	critical	jj
substrate	substrate	nn1
with	with	iw
a	a	at1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
drug	drug	nn1
,	,	y
induced	induce	vvd_jj@_vvn
reinstatement	reinstatement	nn1
.	.	y
Stress-induced	stress-induced	jj_nn1
reinstatement	reinstatement	nn1
of	of	io
drug-related	drug-related	nn1_jj
responding	respond	vvg
in	in	ii
animal	animal	nn1
models	model	nn2
appears	appear	vvz
to	to	to
depend	depend	vvi
on	on	ii
activation	activation	nn1
of	of	io
both	both	rr
CRF	crf	np1
and	and	cc
norepinephrine	norepinephrine	nn1_jj
in	in	ii
elements	element	nn2
of	of	io
the	the	at
extended	extended	jj@
amygdala	amygdala	nn1
(	(	y
central	central	jj
nucleus	nucleus	nn1
of	of	io
the	the	at
amygdala	amygdala	nn1
and	and	cc
BNST		np1
)	)	y
(	(	y
MCFarland	mcfarland	np1
&;		null
Kalivas	kalivas	np2
,	,	y
2001	2001	mc
;	;	y
Shaham	shaham	np1
et	et	ra21
al.	al	ra22
,	,	y
2003	2003	mc
)	)	y
.	.	y
In	in	ii
human	human	jj_nn1
imaging	imaging	nn1_vvg
studies	study	nn2
,	,	y
another	another	dd1
common	common	jj
element	element	nn1
of	of	io
drug	drug	nn1
dependence	dependence	nn1
is	be	vbz
decreased	decrease	vvn_jj@
function	function	nn1
in	in	ii
the	the	at
orbitofrontal/medial	orbitofrontal/medial	jj_nn1
prefrontal	prefrontal	jj
cortex	cortex	nn1
as	as	csa
measured	measure	vvn
both	both	rr
by	by	ii
neuropsychological	neuropsychological	jj
tests	test	nn2
and	and	cc
imaging	imaging	nn1_vvg
:	:	y
(	(	y
Volkow	volkow	np1
&;		null
Li	li	np1
,	,	y
2004	2004	mc
)	)	y
.	.	y
<p>	<p>	y
In	in	ii
summary	summary	nn1
,	,	y
three	three	mc
neurobiological	neurobiological	jj
circuits	circuit	nn2
have	have	vh0
been	be	vbn
identified	identify	vvn
as	as	csa_rg@_ii@
important	important	jj
to	to	ii
the	the	at
study	study	nn1
of	of	io
the	the	at
neurobiological	neurobiological	jj
changes	change	nn2
associated	associate	vvn
with	with	iw
the	the	at
development	development	nn1
and	and	cc
persistence	persistence	nn1
of	of	io
drug	drug	nn1
dependence	dependence	nn1
(	(	y
Koob	koob	np1
&;		null
Le	le	np1
Moal	moal	np1
,	,	y
2006	2006	mc
)	)	y
.	.	y
The	the	at
acute	acute	jj
reinforcing	reinforcing	jj@_vvg
effects	effect	nn2
of	of	io
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
that	that	cst
comprise	comprise	vv0
the	the	at
binge/intoxication	binge/intoxication	nn1
stage	stage	nn1
of	of	io
the	the	at
addiction	addiction	nn1
cycle	cycle	nn1
most	most	rgt_dat
likely	likely	rr@_jj
involve	involve	vv0
actions	action	nn2
localized	localize	vvd_vvn@
to	to	ii
a	a	at1
nucleus	nucleus	nn1
accumbens-amygdala	accumbens-amygdala	nn1_jj
reward	reward	nn1
system	system	nn1
,	,	y
dopamine	dopamine	vv0_nn1
inputs	input	nn2
from	from	ii
the	the	at
ventral	ventral	jj
tegmental	tegmental	jj
area	area	nn1
,	,	y
local	local	jj
opioid	opioid	jj_nn1
peptide	peptide	nn1
circuits	circuit	nn2
,	,	y
and	and	cc
opioid	opioid	jj_nn1
peptide	peptide	nn1
inputs	input	nn2_vvz@
in	in	ii
the	the	at
arcuate	arcuate	jj_nn1
nucleus	nucleus	nn1
of	of	io
the	the	at
hypothalamus	hypothalamus	nn1
.	.	y
In	in	ii
contrast	contrast	nn1
,	,	y
the	the	at
symptoms	symptom	nn2
of	of	io
acute	acute	jj
motivational	motivational	jj
withdrawal	withdrawal	nn1
important	important	jj
for	for	if
addiction	addiction	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
withdrawal/negative	withdrawal/negative	nn1
affect	affect	nn1_vv0
stage	stage	nn1
,	,	y
most	most	rgt_dat
likely	likely	rr@_jj
involve	involve	vv0
decreases	decrease	nn2@_vvz
in	in	ii
function	function	nn1
of	of	io
the	the	at
reward	reward	nn1
system	system	nn1
and	and	cc
recruitment	recruitment	nn1
of	of	io
brain	brain	nn1
stress	stress	nn1
neurocircuitry	neurocircuitry	nn1
.	.	y
The	the	at
**26;5832;TOOLONG		fo
(	(	y
or	or	cc
"	"	y
craving	crave	vvg_nn1@_jj@
"	"	y
)	)	y
stage	stage	nn1
involves	involve	vvz
key	key	jj
afferent	afferent	jj_nn1
projections	projection	nn2
to	to	ii
the	the	at
extended	extended	jj@
amygdala	amygdala	nn1
and	and	cc
nucleus	nucleus	nn1
accumbens	accumbens	nn2
,	,	y
specifically	specifically	rr
the	the	at
prefrontal	prefrontal	jj
cortex	cortex	nn1
(	(	y
for	for	if
drug-induced	drug-induced	jj_nn1
reinstatement	reinstatement	nn1
)	)	y
and	and	cc
the	the	at
basolateral	basolateral	jj_nn1
amygdala	amygdala	nn1
(	(	y
for	for	if
cue-induced	cue-induced	jj_nn1
reinstatement	reinstatement	nn1
)	)	y
.	.	y
Compulsive	compulsive	jj
drug-seeking	drug-seeking	jj_nn1
behavior	behavior	nn1
is	be	vbz
hypothesized	hypothesize	vvn@_jj@
to	to	to
be	be	vbi
driven	drive	vvn
by	by	ii
ventral	ventral	jj
striatal-ventral	striatal-ventral	jj
**26;5860;TOOLONG		jj
loops	loop	nn2
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
MOLECULAR	molecular	jj
APPROACHES	approach	nn2
TO	to	ii
ADDICTION	addiction	npx
Many	many	da2
scientists	scientist	nn2
feel	feel	vv0
that	that	cst
the	the	at
modem	modem	nn1
age	age	nn1
of	of	io
drug	drug	nn1
abuse	abuse	nn1
research	research	nn1
began	begin	vvd
in	in	ii
the	the	at
early	early	jj
1970s	1970s	mc2
with	with	iw
the	the	at
discovery	discovery	nn1
of	of	io
the	the	at
opioid	opioid	jj_nn1
receptors	receptor	nn2
.	.	y
This	this	dd1
discovery	discovery	nn1
was	be	vbdz
made	make	vvn
simultaneously	simultaneously	rr
by	by	ii
three	three	mc
laboratories	laboratory	nn2
,	,	y
including	including	ii_vvg@
that	that	dd1
of	of	io
Eric	eric	np1
J.	xx_j	np1
Simon	simon	np1
,	,	y
(	(	y
Pert	pert	jj
&;		null
Snyder	snyder	nn1
1973	1973	mc
;	;	y
Simon	simon	np1
,	,	y
Hiller	hiller	nn1_np1@
,	,	y
&;		null
Edelman	edelman	np1_nn1
,	,	y
1973	1973	mc
;	;	y
Terenius		np1
,	,	y
1973	1973	mc
)	)	y
.	.	y
The	the	at
discovery	discovery	nn1
that	that	cst_dd1
opiate	opiate	vv0_nn1
analgesics	analgesic	nn2
such	such	ii21
as	as	ii22
morphine	morphine	nn1
or	or	cc
etorphine	etorphine	nn1_vv0
,	,	y
as	as	ii31
well	well	ii32
as	as	ii33
antagonists	antagonist	nn2
such	such	ii21
as	as	ii22
naloxone	naloxone	nn1
and	and	cc
diprenorphine	diprenorphine	nn1_vv0
,	,	y
bind	bind	vv0
stereospecifically	stereospecifically	rr
to	to	ii
animal	animal	nn1
and	and	cc
human	human	jj_nn1
brain	brain	nn1
homogenates	homogenate	nn2_vvz
,	,	y
provided	provided	cs_vvd
the	the	at
initial	initial	jj_nn1
evidence	evidence	nn1
for	for	if
the	the	at
existence	existence	nn1
of	of	io
these	these	dd2
receptors	receptor	nn2
.	.	y
This	this	dd1
was	be	vbdz
quickly	quickly	rr
followed	follow	vvn
by	by	ii
evidence	evidence	nn1
indicating	indicate	vvg
that	that	cst
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
led	lead	vvn_vvd
to	to	ii
a	a	at1
rapid	rapid	jj
increase	increase	nn1
in	in	ii
molecular	molecular	jj
research	research	nn1
on	on	ii
opiates	opiate	nn2
and	and	cc
to	to	ii
several	several	da2
additional	additional	jj
important	important	jj
discoveries	discovery	nn2
in	in	ii
the	the	at
opiate	opiate	nn1
field	field	nn1
.	.	y
One	one	pn1_mc1
was	be	vbdz
the	the	at
finding	finding	nn1
that	that	cst
there	there	ex
are	be	vbr
three	three	mc
types	type	nn2
of	of	io
opioid	opioid	jj_nn1
receptors	receptor	nn2
,	,	y
mu	mu	nn1
(	(	y
MOP	mop	nn1_vv0
)	)	y
,	,	y
delta	delta	nn1
(	(	y
DOP	dop	np1
)	)	y
,	,	y
and	and	cc
kappa	kappa	nn1
(	(	y
KOP	kop	np1
)	)	y
.	.	y
All	all	db
three	three	mc
have	have	vh0
distinct	distinct	jj
distributions	distribution	nn2
in	in	ii
the	the	at
brain	brain	nn1
,	,	y
properties	property	nn2
,	,	y
and	and	cc
actions	action	nn2
.	.	y
The	the	at
Simon	simon	np1
laboratory	laboratory	nn1
pioneered	pioneer	vvd_vvn
the	the	at
purification	purification	nn1
of	of	io
these	these	dd2
receptors	receptor	nn2
,	,	y
making	make	vvg
pure	pure	jj
proteins	protein	nn2
available	available	jj
to	to	ii
investigators	investigator	nn2
for	for	if
structural	structural	jj
and	and	cc
functional	functional	jj
studies	study	nn2
(	(	y
Gioannini		np1_nn1
,	,	y
Howard	howard	np1
,	,	y
Hiller	hiller	nn1_np1@
,	,	y
&;		null
Simon	simon	np1
,	,	y
1985	1985	mc
)	)	y
.	.	y
Such	such	da
pure	pure	jj
receptors	receptor	nn2
were	be	vbdr
reconstituted	reconstitute	vvn
with	with	iw
pure	pure	jj
G-proteins	g-proteins	nn2
and	and	cc
phospholipids	phospholipid	nn2
to	to	to
form	form	vvi
an	a	at1
active	active	jj
complex	complex	nn1_jj
,	,	y
able	able	jk
to	to	to
bind	bind	vvi
both	both	rr_db2
opioid	opioid	jj
agonists	agonist	nn2
and	and	cc
antagonists	antagonist	nn2
with	with	iw
high	high	jj
affinity	affinity	nn1
in	in	rr21_jj21
vitro	vitro	rr22_jj22
(	(	y
Gioannini		np1
et	et	ra21
al.	al	ra22
,	,	y
1993	1993	mc
)	)	y
.	.	y
<p>	<p>	y
Scientists	scientist	nn2
posed	pose	vvd_vvn
the	the	at
obvious	obvious	jj
question	question	nn1
:	:	y
Why	why	rrq
are	be	vbr
there	there	rl_ex
receptors	receptor	nn2
in	in	ii
the	the	at
brain	brain	nn1
that	that	cst
bind	bind	vv0
morphine	morphine	nn1
and	and	cc
synthetic	synthetic	jj
drugs	drug	nn2
?	?	y
Why	why	rrq
have	have	vh0
these	these	dd2
receptors	receptor	nn2
survived	survive	vvn
eons	eon	nn2
of	of	io
evolution	evolution	nn1
?	?	y
What	what	ddq
is	be	vbz
their	their	appge
real	real	jj
physiological	physiological	jj
function	function	nn1
?	?	y
This	this	dd1
led	lead	vvd_vvn
to	to	ii
the	the	at
next	next	md
important	important	jj
<p>	<p>	y
What	what	ddq
is	be	vbz
the	the	at
value	value	nn1
of	of	io
knowing	know	vvg
the	the	at
DNA	dna	nn1
structures	structure	nn2
(	(	y
nucleotide	nucleotide	vv0_nn1
sequences	sequence	nn2
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
?	?	y
DNA	dna	nn1
cloning	cloning	nn1
has	have	vhz
led	lead	vvn
to	to	ii
significant	significant	jj
advances	advance	nn2
in	in	ii
techniques	technique	nn2
that	that	cst
have	have	vh0
had	have	vhn
a	a	at1
huge	huge	jj
impact	impact	nn1
on	on	ii
biomedical	biomedical	jj
research	research	nn1
.	.	y
Some	some	dd
of	of	io
these	these	dd2
techniques	technique	nn2
are	be	vbr
explained	explain	vvn
here	here	rl
,	,	y
with	with	iw
a	a	at1
focus	focus	nn1
on	on	ii
their	their	appge
applications	application	nn2
to	to	ii
the	the	at
study	study	nn1
of	of	io
opioids	opioid	nn2
(	(	y
Table	table	nn1
4	4	mc
)	)	y
.	.	y
<p>	<p>	y
breakthrough	breakthrough	nn1
,	,	y
the	the	at
discovery	discovery	nn1
of	of	io
substances	substance	nn2
in	in	ii
the	the	at
brain	brain	nn1
and	and	cc
other	other	jj
tissues	tissue	nn2
with	with	iw
morphine-like	morphine-like	jj
activity	activity	nn1
,	,	y
often	often	rr
called	call	vvn
endorphins	endorphin	nn2
(	(	y
a	a	at1
term	term	nn1
coined	coin	vvd_vvn@
by	by	ii
Simon	simon	np1
)	)	y
.	.	y
These	these	dd2
substances	substance	nn2
were	be	vbdr
determined	determine	vvn
to	to	to
be	be	vbi
peptides	peptide	nn2
(	(	y
short	short	jj
chains	chain	nn2
of	of	io
amino	amino	nn1
acids	acid	nn2
,	,	y
ranging	range	vvg
in	in	ii
size	size	nn1
from	from	ii
5	5	mc
amino	amino	nn1
acids	acid	nn2
for	for	if
enkephalins	enkephalin	nn2
to	to	ii
32	32	mc
amino	amino	nn1
acids	acid	nn2
for	for	if
beta-endorphin	beta-endorphin	nn1_jj
)	)	y
,	,	y
Table	table	nn1
3	3	mc
lists	list	vvz_nn2
the	the	at
known	known	jj@
opioid	opioid	jj_nn1
peptides	peptide	nn2
and	and	cc
their	their	appge
amino	amino	nn1
acid	acid	nn1
sequences	sequence	nn2
,	,	y
expressed	express	vvn_vvd
in	in	ii
the	the	at
single-letter	single-letter	jj_nn1
nomenclature	nomenclature	nn1
of	of	io
amino	amino	nn1
acids	acid	nn2
,	,	y
such	such	ii21
as	as	ii22
Y	y	zz1_np1@
for	for	if
Tyrosine	tyrosine	np1
,	,	y
G	g	zz1
for	for	if
glycine	glycine	nn1
,	,	y
etc.	etc	ra
(	(	y
the	the	at
complete	complete	jj
list	list	nn1
of	of	io
amino	amino	nn1
acid	acid	nn1
single-letter	single-letter	nn1_jj
sequences	sequence	nn2
is	be	vbz
readily	readily	rr
available	available	jj
in	in	ii
any	any	dd
biochemistry	biochemistry	nn1
textbook	textbook	nn1
for	for	if
those	those	dd2
who	who	pnqs
are	be	vbr
interested	interested	jj
)	)	y
.	.	y
J	xx_j	zz1_np1@
<p>	<p>	y
A	a	at1_zz1
series	series	nn
of	of	io
exciting	exciting	jj
and	and	cc
outstanding	outstanding	jj
studies	study	nn2
led	lead	vvn_vvd
to	to	ii
an	a	at1
understanding	understanding	nn1
of	of	io
how	how	rrq
these	these	dd2
opioid	opioid	jj
peptides	peptide	nn2
are	be	vbr
biosynthesized	biosynthesized	vvn@_jj@
(	(	y
see	see	vv0
Simon	simon	np1
&;		null
Hiller	hiller	np1@_nn1
,	,	y
1994	1994	mc
)	)	y
.	.	y
All	all	db
of	of	io
them	them	ppho2
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
,	,	y
proenkephalin	proenkephalin	nn1
,	,	y
and	and	cc
prodynorphin	prodynorphin	nn1
.	.	y
Opiomelanocortin	opiomelanocortin	nn1_np1@
is	be	vbz
of	of	io
particular	particular	jj
interest	interest	nn1
because	because	cs
it	it	pph1
is	be	vbz
the	the	at
precursor	precursor	nn1
for	for	if
several	several	da2
important	important	jj
and	and	cc
seemingly	seemingly	rr
unrelated	unrelated	jj
biologically	biologically	rr
active	active	jj
molecules	molecule	nn2
,	,	y
namely	namely	rex
,	,	y
b-endorphin	b-endorphin	nn1_jj
,	,	y
adrenocorticotropic	adrenocorticotropic	jj
hormone	hormone	nn1
,	,	y
and	and	cc
several	several	da2
melanocyte-stimulating	melanocyte-stimulating	jj
hormones	hormone	nn2
.	.	y
<p>	<p>	y
Once	once	rr_cs@
these	these	dd2
precursors	precursor	nn2
and	and	cc
their	their	appge
structures	structure	nn2
were	be	vbdr
known	know	vvn
,	,	y
there	there	ex
was	be	vbdz
a	a	at1
race	race	nn1
to	to	to_ii
Clone	clone	vv0
them	them	ppho2
.	.	y
The	the	at
term	term	nn1
cloning	cloning	nn1
is	be	vbz
an	a	at1
unfortunate	unfortunate	jj
term	term	nn1
It	it	pph1
refers	refer	vvz
here	here	rl
to	to	ii
the	the	at
purification	purification	nn1
I	i	zz1%_mc1%_ppis1
.	.	y
!	!	y
and	and	cc
nucleotide	nucleotide	vv0_nn1
sequencing	sequencing	nn1
of	of	io
the	the	at
DNA	dna	nn1
of	of	io
a	a	at1
gene	gene	nn1
.	.	y
The	the	at
structure	structure	nn1
of	of	io
the	the	at
protein	protein	nn1
can	can	vm
then	then	rt
be	be	vbi
inferred	infer	vvn
by	by	ii
using	use	vvg
the	the	at
universal	universal	jj
genetic	genetic	jj
code	code	nn1
to	to	to
translate	translate	vvi
nucleotide	nucleotide	nn1
triplets	triplet	nn2
(	(	y
codons	codon	nn2
)	)	y
into	into	ii
amino	amino	nn1
acids	acid	nn2
The	the	at
structure	structure	nn1
of	of	io
the	the	at
full	full	jj
gene	gene	nn1
with	with	iw
its	its	z'
long	long	jj
introns	intron	nn2
can	can	vm
also	also	rr
be	be	vbi
readily	readily	rr
attained	attain	vvn_vvd
.	.	y
The	the	at
DNA	dna	nn1
sequences	sequence	nn2
were	be	vbdr
successfully	successfully	rr
determined	determine	vvn
for	for	if
the	the	at
genes	gene	nn2
encoding	encode	vvg
the	the	at
three	three	mc
opioid	opioid	jj
peptide	peptide	nn1
precursors	precursor	nn2
,	,	y
the	the	at
first	first	md
of	of	io
which	which	ddq
was	be	vbdz
the	the	at
opiomelanocortin	opiomelanocortin	nn1
gene	gene	nn1
(	(	y
Noda	noda	np1
et	et	ra21
al.	al	ra22
,	,	y
1982	1982	mc
)	)	y
.	.	y
<p>	<p>	y
More	more	rgr_rrr
recently	recently	rr
,	,	y
the	the	at
gene	gene	nn1
and	and	cc
protein	protein	nn1
sequences	sequence	nn2
for	for	if
the	the	at
three	three	mc
types	type	nn2
of	of	io
opioid	opioid	jj_nn1
receptors	receptor	nn2
also	also	rr
have	have	vh0
been	be	vbn
identified	identify	vvn
.	.	y
The	the	at
first	first	md
to	to	to
be	be	vbi
cloned	clone	vvn@
was	be	vbdz
the	the	at
delta	delta	nn1
receptor	receptor	nn1
(	(	y
Evans	evans	np1
,	,	y
Keith	keith	np1
,	,	y
Morrison	morrison	np1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
Befort		np1_vv0_nn1
,	,	y
Ruff	ruff	nn1
,	,	y
&;		null
Hirth	hirth	np1_nn1
,	,	y
1992	1992	mc
)	)	y
.	.	y
All	all	db
three	three	mc
types	type	nn2
have	have	vh0
since	since	rr@
been	be	vbn
cloned	clone	vvn@
,	,	y
and	and	cc
no	no	at
genes	gene	nn2
for	for	if
additional	additional	jj
opioid	opioid	jj_nn1
receptor	receptor	nn1
types	type	nn2
have	have	vh0
subsequently	subsequently	rr
been	be	vbn
discovered	discover	vvn@
.	.	y
The	the	at
knowledge	knowledge	nn1
of	of	io
the	the	at
sequence	sequence	nn1
of	of	io
the	the	at
"	"	y
reading	reading	nn1
frame	frame	nn1
"	"	y
of	of	io
the	the	at
genes	gene	nn2
and	and	cc
the	the	at
resulting	resulting	jj
knowledge	knowledge	nn1
of	of	io
the	the	at
amino	amino	nn1
acid	acid	nn1
sequence	sequence	nn1
of	of	io
the	the	at
receptor	receptor	nn1
proteins	protein	nn2
confirmed	confirm	vvd_vvn
previous	previous	jj
pharmacological	pharmacological	jj
studies	study	nn2
that	that	cst
had	have	vhd
suggested	suggest	vvn
opioid	opioid	jj_nn1
receptors	receptor	nn2
are	be	vbr
members	member	nn2
of	of	io
the	the	at
large	large	jj
family	family	nn1
of	of	io
G	g	zz1
protein-coupled	protein-coupled	jj
receptors	receptor	nn2
and	and	cc
have	have	vh0
the	the	at
typical	typical	jj
structure	structure	nn1
of	of	io
such	such	da
receptors	receptor	nn2
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
SITE-DIRECTED	site-directed	jj
MUTATIONS	mutation	nn2
AND	and	cc
DELETIONS		np1_nn2
The	the	at
DNA	dna	nn1
of	of	io
a	a	at1
gene	gene	nn1
can	can	vm
be	be	vbi
manipulated	manipulate	vvn
by	by	ii
creating	create	vvg
mutations	mutation	nn2
,	,	y
replacing	replace	vvg
or	or	cc
deleting	delete	vvg
nucleotides	nucleotide	nn2
that	that	cst
change	change	vv0
the	the	at
code	code	nn1
for	for	if
an	a	at1
amino	amino	nn1
acid	acid	nn1
,	,	y
and	and	cc
eliminating	eliminate	vvg
a	a	at1
portion	portion	nn1
of	of	io
the	the	at
gene	gene	nn1
.	.	y
Thus	thus	rr
,	,	y
the	the	at
codon	codon	nn1
for	for	if
a	a	at1
single	single	jj
amino	amino	nn1
acid	acid	nn1
in	in	ii
a	a	at1
crucial	crucial	jj
area	area	nn1
of	of	io
the	the	at
molecule	molecule	nn1
can	can	vm
be	be	vbi
altered	alter	vvn_jj
or	or	cc
a	a	at1
portion	portion	nn1
of	of	io
the	the	at
DNA	dna	nn1
deleted	delete	vvd_vvn
,	,	y
such	such	ii21
as	as	ii22
the	the	at
DNA	dna	nn1
coding	code	vvg_nn1
for	for	if
the	the	at
carboxyl	carboxyl	nn1
tail	tail	nn1
of	of	io
an	a	at1
opioid	opioid	jj_nn1
receptor	receptor	nn1
.	.	y
Such	such	da
altered	altered	jj
genes	gene	nn2
then	then	rt
can	can	vm
be	be	vbi
introduced	introduce	vvn
into	into	ii
cells	cell	nn2
in	in	ii
culture	culture	nn1
or	or	cc
into	into	ii
animals	animal	nn2
,	,	y
and	and	cc
the	the	at
effects	effect	nn2
of	of	io
these	these	dd2
changes	change	nn2
on	on	ii
the	the	at
phenotype	phenotype	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
One	one	pn1_mc1
can	can	vm
now	now	rt
take	take	vvi
part	part	nn1
of	of	io
the	the	at
DNA	dna	nn1
encoding	encode	vvg
one	one	mc1
molecule	molecule	nn1
(	(	y
e.g.	eg	rex
,	,	y
the	the	at
mu	mu	nn1
opioid	opioid	nn1_jj
receptor	receptor	nn1
)	)	y
and	and	cc
another	another	dd1
portion	portion	nn1
of	of	io
the	the	at
DNA	dna	nn1
encoding	encode	vvg
another	another	dd1
molecule	molecule	nn1
(	(	y
e.g.	eg	rex
,	,	y
the	the	at
delta	delta	nn1
opioid	opioid	nn1_jj
receptor	receptor	nn1
)	)	y
and	and	cc
create	create	vv0
a	a	at1
chimera	chimera	nn1
.	.	y
One	one	pn1
can	can	vm
then	then	rt
ask	ask	vvi
questions	question	nn2
about	about	ii
which	which	ddq
properties	property	nn2
and	and	cc
functions	function	nn2
come	come	vv0_vvn@
from	from	ii
one	one	mc1
or	or	cc
the	the	at
other	other	jj
receptor	receptor	nn1
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
KNOCKOUT	knockout	np1_vv0_nn1
AND	and	cc
TRANSGENIC	transgenic	jj_np1
ANIMALS	animal	nn2
It	it	pph1
is	be	vbz
possible	possible	jj
to	to	to
generate	generate	vvi
knockout	knockout	nn1
or	or	cc
transgenic	transgenic	jj
animals	animal	nn2
.	.	y
Mice	mouse	nn2
are	be	vbr
most	most	rgt
commonly	commonly	rr
used	use	vvn_vvd
for	for	if
this	this	dd1
purpose	purpose	nn1
.	.	y
Knockout	knockout	vv0_nn1
mice	mouse	nn2
are	be	vbr
those	those	dd2
that	that	cst
have	have	vh0
only	only	rr
an	a	at1
inactive	inactive	jj
form	form	nn1
of	of	io
the	the	at
gene	gene	nn1
under	under	ii
study	study	nn1
and	and	cc
therefore	therefore	rr
lack	lack	vv0@
an	a	at1
active	active	jj
protein	protein	nn1
(	(	y
e.g.	eg	rex
,	,	y
one	one	mc1
or	or	cc
more	more	dar
of	of	io
the	the	at
opioid	opioid	jj_nn1
receptors	receptor	nn2
or	or	cc
peptides	peptide	nn2
)	)	y
.	.	y
A	a	at1_zz1
transgenic	transgenic	jj
mouse	mouse	nn1
has	have	vhz
a	a	at1
gene	gene	nn1
that	that	cst_dd1
has	have	vhz
been	be	vbn
transferred	transfer	vvn
and	and	cc
is	be	vbz
not	not	xx
normally	normally	rr
expressed	express	vvn
(	(	y
e.g.	eg	rex
,	,	y
a	a	at1
gene	gene	nn1
for	for	if
the	the	at
human	human	jj_nn1
opioid	opioid	jj_nn1
receptor	receptor	nn1
or	or	cc
a	a	at1
molecule	molecule	nn1
it	it	pph1
does	do	vdz
not	not	xx
normally	normally	rr
make	make	vvi
or	or	cc
a	a	at1
gene	gene	nn1
that	that	cst_dd1
has	have	vhz
been	be	vbn
manipulated	manipulate	vvn
by	by	ii
mutation	mutation	nn1
or	or	cc
deletion	deletion	nn1
)	)	y
.	.	y
The	the	at
phenotype	phenotype	nn1
of	of	io
such	such	da
mice	mouse	nn2
can	can	vm
now	now	rt
be	be	vbi
probed	probe	vvn
by	by	ii
behavioral	behavioral	nn1_jj
,	,	y
electrophysiological	electrophysiological	jj
,	,	y
pharmacological	pharmacological	jj
,	,	y
and	and	cc
metabolic	metabolic	jj
measurements	measurement	nn2
to	to	to
determine	determine	vvi
the	the	at
impact	impact	nn1
of	of	io
the	the	at
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
Kieffer	kieffer	np1
&;		null
Gaveriaux-Ruff		np1
,	,	y
2002	2002	mc
)	)	y
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
MICROARRAYS	microarray	np2_vvz_nn2
TO	to	to
STUDY	study	vvi
GENE	gene	nn1
EXPRESSION	expression	nn1
Microarrays	microarray	nn2_vvz_np1
,	,	y
arrays	array	nn2
of	of	io
thousands	thousand	m
of	of	io
genes	gene	nn2
of	of	io
interest	interest	nn1
on	on	ii
a	a	at1
tiny	tiny	jj
chip	chip	nn1
,	,	y
have	have	vh0
recently	recently	rr
become	become	vv0
available	available	jj
.	.	y
Only	only	rr
those	those	dd2
genes	gene	nn2
that	that	cst_dd1
anneal	anneal	jj
with	with	iw
messenger	messenger	nn1
RNA	rna	nn1
(	(	y
the	the	at
gene	gene	nn1
product	product	nn1
that	that	cst_dd1
is	be	vbz
the	the	at
intermediate	intermediate	jj
for	for	if
protein	protein	nn1
synthesis	synthesis	nn1
)	)	y
from	from	ii
the	the	at
tissue	tissue	nn1
under	under	ii
study	study	nn1
are	be	vbr
expressed	express	vvn
in	in	ii
that	that	dd1
tissue	tissue	nn1
and	and	cc
under	under	ii
the	the	at
given	given	jj@
physiological	physiological	jj
or	or	cc
pathological	pathological	jj
conditions	condition	nn2
.	.	y
This	this	dd1
allows	allow	vvz
changes	change	nn2
in	in	ii
the	the	at
level	level	nn1
of	of	io
gene	gene	nn1
expression	expression	nn1
in	in	ii
various	various	jj
physiological	physiological	jj
of	of	io
pathological	pathological	jj
conditions	condition	nn2
to	to	to
be	be	vbi
determined	determine	vvn
.	.	y
For	for	rex21
example	example	rex22
,	,	y
one	one	pn1
can	can	vm
ask	ask	vvi
what	what	ddq
brain	brain	nn1_vv0%
genes	gene	nn2
are	be	vbr
turned	turn	vvn
up	up	rp
,	,	y
turned	turn	vvd_vvn
down	down	rp
,	,	y
or	or	cc
turned	turn	vvd_vvn
on	on	rp@_ii
or	or	cc
off	off	rp
,	,	y
when	when	cs_rrq
a	a	at1
dependent	dependent	jj
rat	rat	nn1
is	be	vbz
withdrawn	withdraw	vvn
from	from	ii
a	a	at1
drug	drug	nn1
or	or	cc
when	when	cs_rrq
an	a	at1
animal	animal	nn1
is	be	vbz
given	give	vvn_jj@
cues	cue	nn2
that	that	cst
lead	lead	vv0_nn1
to	to	ii
craving	crave	vvg
for	for	if
a	a	at1
drug	drug	nn1
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
STUDY	study	nn1
OF	of	io
SINGLE	single	jj
NUCLEOTIDE	nucleotide	nn1
POLYMORPHISMS	polymorphism	nn2
AND	and	cc
OTHER	other	jj
GENETIC	genetic	jj
VARIANTS	variant	nn2
Many	many	da2
mutations	mutation	nn2
(	(	y
alleles	allele	nn2
)	)	y
exist	exist	vv0
in	in	ii_rp@
human	human	nn1_jj
and	and	cc
animal	animal	nn1
cells	cell	nn2
and	and	cc
often	often	rr
do	do	vd0
not	not	xx
drastically	drastically	rr
change	change	vvi
the	the	at
phenotype	phenotype	nn1
but	but	ccb
rather	rather	rr@
could	could	vm
produce	produce	vvi
subtle	subtle	jj
changes	change	nn2
.	.	y
The	the	at
reason	reason	nn1
for	for	if
the	the	at
relatively	relatively	rr
mild	mild	jj
effects	effect	nn2
of	of	io
such	such	da
mutants	mutant	nn2
is	be	vbz
either	either	rr
because	because	cs
the	the	at
altered	altered	jj
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
essential	essential	jj
for	for	if
the	the	at
function	function	nn1
of	of	io
the	the	at
protein	protein	nn1
or	or	cc
because	because	cs
the	the	at
change	change	nn1
in	in	ii
the	the	at
nucleotide	nucleotide	nn1
does	do	vdz
not	not	xx
result	result	vvi
in	in	ii
a	a	at1
change	change	nn1
in	in	ii
the	the	at
amino	amino	nn1
acid	acid	nn1
.	.	y
Such	such	da
natural	natural	jj
mutations	mutation	nn2
are	be	vbr
called	call	vvn
single	single	jj
nucleotide	nucleotide	nn1
polymorphisms	polymorphism	nn2
(	(	y
SNPs	snps	np2
)	)	y
.	.	y
Many	many	da2
laboratories	laboratory	nn2
are	be	vbr
now	now	rt
attempting	attempt	vvg
to	to	to
determine	determine	vvi
whether	whether	csw
such	such	da
SNPs	snps	np2
have	have	vh0
subtle	subtle	jj
effects	effect	nn2
on	on	ii
phenotype	phenotype	nn1
and	and	cc
thus	thus	rr
may	may	vm
contribute	contribute	vvi
,	,	y
for	for	rex21
example	example	rex22
,	,	y
to	to	ii
the	the	at
striking	striking	jj
differences	difference	nn2
observed	observe	vvn_vvd
between	between	ii
individuals	individual	nn2
in	in	ii
their	their	appge
sensitivity	sensitivity	nn1
to	to	ii
the	the	at
addicting	addicting	jj@_nn1@
effects	effect	nn2
of	of	io
abused	abused	jj@
drugs	drug	nn2
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
SPECIES	species	nn
DIFFERENCES	difference	nn2
AND	and	cc
EVOLUTIONARY	evolutionary	jj
CHANGES	change	nn2
IN	in	ii
GENE	gene	nn1_np1@
STRUCTURE	structure	nn1
The	the	at
complete	complete	jj
sequencing	sequencing	nn1
of	of	io
the	the	at
human	human	jj_nn1
genome	genome	nn1
and	and	cc
that	that	dd1
of	of	io
many	many	da2
other	other	jj
creatures	creature	nn2
,	,	y
animals	animal	nn2
,	,	y
microorganisms	microorganism	nn2
,	,	y
and	and	cc
plants	plant	nn2
,	,	y
has	have	vhz
made	make	vvn
possible	possible	jj
the	the	at
study	study	nn1
of	of	io
changes	change	nn2
in	in	ii
gene	gene	nn1
structure	structure	nn1
as	as	csa_rg@
never	never	rr
before	before	rt
These	these	dd2
advances	advance	nn2
have	have	vh0
already	already	rr
improved	improve	vvn
understanding	understanding	nn1
of	of	io
species	species	nn
differences	difference	nn2
and	and	cc
of	of	io
the	the	at
workings	working	nn2
of	of	io
evolution	evolution	nn1
.	.	y
Such	such	da
genomic	genomic	jj
approaches	approach	nn2
will	will	vm
likely	likely	rr@
further	far	rrr
our	our	appge
understanding	understanding	nn1
,	,	y
prevention	prevention	nn1
,	,	y
and	and	cc
treatment	treatment	nn1
of	of	io
human	human	jj_nn1
diseases	disease	nn2
.	.	y
including	including	ii
drug	drug	nn1
addiction	addiction	nn1
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
STUDIES	study	nn2
OF	of	io
GENE	gene	nn1_np1@
EXPRESSION	expression	nn1
AND	and	cc
PROMOTER	promoter	nn1
REGULATION	regulation	nn1
BY	by	ii
TRANSCRIPTION	transcription	nn1
FACTORS	factor	nn2
Finally	finally	rr
,	,	y
studies	study	nn2
in	in	ii
which	which	ddq
levels	level	nn2
of	of	io
gene	gene	nn1
expression	expression	nn1
and	and	cc
promoter	promoter	nn1
regulation	regulation	nn1
by	by	ii
proteins	protein	nn2
called	call	vvn_vvd@
transcription	transcription	nn1
factors	factor	nn2
are	be	vbr
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
promoter	promoter	nn1
region	region	nn1
,	,	y
where	where	cs_rrq
gene	gene	nn1
activity	activity	nn1
is	be	vbz
turned	turn	vvn
on	on	rp@_ii
or	or	cc
off	off	rp
,	,	y
and	and	cc
where	where	rrq_cs
,	,	y
when	when	cs_rrq
on	on	ii_rp@
,	,	y
the	the	at
level	level	nn1
of	of	io
gene	gene	nn1
transcription	transcription	nn1
is	be	vbz
regulated	regulate	vvn
.	.	y
Understanding	understand	vvg_nn1
how	how	rrq
gene	gene	nn1
expression	expression	nn1
is	be	vbz
regulated	regulate	vvn
is	be	vbz
of	of	io
considerable	considerable	jj
importance	importance	nn1
.	.	y
These	these	dd2
sophisticated	sophisticated	jj
experiments	experiment	nn2
are	be	vbr
best	best	rrt
performed	perform	vvn
in	in	ii
cell	cell	nn1
culture	culture	nn1
,	,	y
although	although	cs
studies	study	nn2
in	in	ii
animals	animal	nn2
are	be	vbr
becoming	become	vvg
more	more	rrr_dar_rgr
and	and	cc
more	more	rgr
possible	possible	jj
Numerous	numerous	jj
transcription	transcription	nn1
factors	factor	nn2
have	have	vh0
already	already	rr
been	be	vbn
discovered	discover	vvn@
,	,	y
resulting	result	vvg
in	in	ii
a	a	at1
better	better	jjr
understanding	understanding	nn1
of	of	io
how	how	rrq
gene	gene	nn1
transcription	transcription	nn1
and	and	cc
replication	replication	nn1
are	be	vbr
controlled	control	vvn
.	.	y
The	the	at
cloning	cloning	nn1
of	of	io
genes	gene	nn2
has	have	vhz
led	lead	vvn
to	to	ii
numerous	numerous	jj
experimental	experimental	jj
approaches	approach	nn2
that	that	cst
were	be	vbdr
heretofore	heretofore	rr
impossible	impossible	jj
,	,	y
and	and	cc
many	many	da2
of	of	io
these	these	dd2
are	be	vbr
powerful	powerful	jj
techniques	technique	nn2
that	that	cst
are	be	vbr
already	already	rr
providing	provide	vvg
information	information	nn1
we	we	ppis2
never	never	rr
dreamed	dream	vvn_vvd
of	of	io
being	be	vbg
able	able	jk
to	to	to
obtain	obtain	vvi
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
SIGNAL	signal	nn1_vv0@
TRANSDUCTION	transduction	nn1_np1
The	the	at
final	final	jj_nn1
topic	topic	nn1
to	to	to
be	be	vbi
discussed	discuss	vvn
is	be	vbz
the	the	at
exciting	exciting	jj
research	research	nn1
area	area	nn1
known	know	vvn
as	as	ii
signal	signal	nn1
transduction	transduction	nn1
.	.	y
These	these	dd2
investigations	investigation	nn2
probe	probe	vv0
the	the	at
chemical	chemical	jj_nn1
reactions	reaction	nn2
that	that	cst
allow	allow	vv0
the	the	at
signal	signal	nn1
generated	generate	vvn
by	by	ii
a	a	at1
ligand	ligand	nn1
(	(	y
e.g.	eg	rex
,	,	y
opiate	opiate	vv0_nn1
drug	drug	nn1
or	or	cc
opioid	opioid	jj_nn1
peptide	peptide	nn1
)	)	y
binding	bind	vvg
to	to	ii
a	a	at1
receptor	receptor	nn1
to	to	to
be	be	vbi
transduced	transduce	vvn@
to	to	ii
the	the	at
site	site	nn1
at	at	ii
which	which	ddq
the	the	at
action	action	nn1
of	of	io
the	the	at
ligand	ligand	nn1
or	or	cc
drug	drug	nn1
takes	take	vvz
place	place	nn1
.	.	y
Numerous	numerous	jj
laboratories	laboratory	nn2
have	have	vh0
made	make	vvn
much	much	da1
progress	progress	nn1
in	in	ii
our	our	appge
understanding	understanding	nn1
of	of	io
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
in	in	ii
this	this	dd1
area	area	nn1
is	be	vbz
the	the	at
study	study	nn1
of	of	io
opioid	opioid	jj_nn1
receptors	receptor	nn2
(	(	y
and	and	cc
other	other	jj
G	g	zz1
protein-coupled	protein-coupled	jj
receptors	receptor	nn2
)	)	y
where	where	rrq_cs
there	there	ex
is	be	vbz
activation	activation	nn1
of	of	io
protein-phosphorylating	protein-phosphorylating	jj_nn1
enzymes	enzyme	nn2
,	,	y
called	call	vvn_vvd@
mitogen-activated	mitogen-activated	jj_nn1
protein	protein	nn1
(	(	y
MAP	map	nn1
)	)	y
kinases	kinase	nn2
.	.	y
This	this	dd1
ability	ability	nn1
had	have	vhd
previously	previously	rr
been	be	vbn
thought	think	vvn
to	to	to
be	be	vbi
restricted	restrict	vvn
to	to	ii
hormone	hormone	nn1
and	and	cc
growth	growth	nn1
factor	factor	nn1
receptors	receptor	nn2
.	.	y
These	these	dd2
MAP	map	nn1_vv0@
kinases	kinase	nn2
are	be	vbr
known	know	vvn
to	to	to
be	be	vbi
involved	involved	jj
in	in	ii
changes	change	nn2
in	in	ii
gene	gene	nn1
expression	expression	nn1
,	,	y
via	via	ii
phosphorylation	phosphorylation	nn1
of	of	io
transcription	transcription	nn1
factors	factor	nn2
,	,	y
clearly	clearly	rr
important	important	jj
for	for	if
the	the	at
type	type	nn1
of	of	io
adaptations	adaptation	nn2
seen	see	vvn
in	in	ii
drug	drug	nn1
dependence	dependence	nn1
.	.	y
The	the	at
Simon	simon	np1
laboratory	laboratory	nn1
and	and	cc
that	that	dd1
of	of	io
Susan	susan	np1
George	george	np1
were	be	vbdr
able	able	jk
to	to	to
show	show	vvi
independently	independently	rr
that	that	dd1_cst
MAP	map	nn1
kinase	kinase	nn1
activation	activation	nn1
involves	involve	vvz
phosphorylation	phosphorylation	nn1
of	of	io
tyrosine	tyrosine	nn1
residues	residue	nn2
on	on	ii
the	the	at
delta	delta	nn1
and	and	cc
mu	mu	nn1
opioid	opioid	nn1_jj
receptors	receptor	nn2
,	,	y
respectively	respectively	rr
(	(	y
Kramer	kramer	np1_nn1
,	,	y
Andria	andria	np1
,	,	y
Esposito	esposito	np1_nn1
,	,	y
&;		null
Simon	simon	np1
,	,	y
2000	2000	mc
;	;	y
Pak	pak	np1
,	,	y
O'Dowd	o'dowd	np1
,	,	y
Wang	wang	np1
,	,	y
&;		null
George	george	np1
,	,	y
1999	1999	mc
)	)	y
.	.	y
An	a	at1
understanding	understanding	nn1
of	of	io
signal	signal	nn1
transduction	transduction	nn1
pathways	pathway	nn2
could	could	vm
lead	lead	vvi
to	to	ii
very	very	rg
specific	specific	jj
interference	interference	nn1
with	with	iw
a	a	at1
particular	particular	jj
step	step	nn1
,	,	y
such	such	ii21
as	as	ii22
a	a	at1
step	step	nn1
involved	involved	jj
in	in	ii
the	the	at
development	development	nn1
of	of	io
tolerance	tolerance	nn1
,	,	y
physical	physical	jj
dependence	dependence	nn1
,	,	y
or	or	cc
craving	crave	vvg
for	for	if
drugs	drug	nn2
.	.	y
<p>	<p>	y
One	one	mc1
dramatic	dramatic	jj
example	example	nn1
comes	come	vvz
from	from	ii
the	the	at
cancer	cancer	nn1
field	field	nn1
(	(	y
Schiffer	schiffer	np1
,	,	y
2007	2007	mc
)	)	y
.	.	y
Cancer	cancer	nn1
cells	cell	nn2
in	in	ii
chronic	chronic	jj
myelogenous	myelogenous	jj
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
)	)	y
that	that	dd1_cst
is	be	vbz
not	not	xx
present	present	jj_nn1_vv0@
in	in	ii_rp@
exactly	exactly	rr
the	the	at
same	same	da
form	form	nn1
in	in	ii
normal	normal	jj
host	host	nn1
cells	cell	nn2
.	.	y
A	a	at1
drug	drug	nn1
has	have	vhz
been	be	vbn
developed	develop	vvn
that	that	cst_dd1
specifically	specifically	rr
inhibits	inhibit	vvz
this	this	dd1
cancer	cancer	nn1
cell	cell	nn1
enzyme	enzyme	nn1
with	with	iw
little	little	jj_da1
or	or	cc
no	no	at
effects	effect	nn2
on	on	ii
host	host	nn1
cell	cell	nn1
kinases	kinase	nn2
.	.	y
This	this	dd1
drug	drug	nn1
is	be	vbz
called	call	vvn
Gleevec	gleevec	np1
and	and	cc
is	be	vbz
remarkably	remarkably	rr
effective	effective	jj
in	in	ii
CML	cml	mc
,	,	y
with	with	iw
little	little	jj_da1
or	or	cc
no	no	at
side	side	nn1
effects	effect	nn2
.	.	y
The	the	at
effects	effect	nn2
on	on	ii
CML	cml	mc
and	and	cc
some	some	dd
other	other	jj
cancers	cancer	nn2
have	have	vh0
been	be	vbn
so	so	rg_rr
dramatic	dramatic	jj
that	that	cst
some	some	dd
physicians	physician	nn2
have	have	vh0
called	call	vvn
this	this	dd1
treatment	treatment	nn1
a	a	at1
cure	cure	nn1
.	.	y
<p>	<p>	y
Clearly	clearly	rr
this	this	dd1
is	be	vbz
the	the	at
future	future	nn1_jj
,	,	y
to	to	to
try	try	vvi
to	to	to
develop	develop	vvi
highly	highly	rr
specific	specific	jj
treatments	treatment	nn2
for	for	if
all	all	db
human	human	jj
diseases	disease	nn2
that	that	cst
produce	produce	vv0
minimal	minimal	jj
secondary	secondary	jj_nn1
effects	effect	nn2
because	because	ii21
of	of	ii22
the	the	at
specificity	specificity	nn1
of	of	io
action	action	nn1
.	.	y
Signal	signal	nn1_vv0@
transduction	transduction	nn1
pathways	pathway	nn2
are	be	vbr
just	just	rr
one	one	mc1
of	of	io
the	the	at
places	place	nn2
to	to	to
look	look	vvi
for	for	if
possible	possible	jj
targets	target	nn2
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
WHERE	where	rrq_cs
WE	we	ppis2
ARE	be	vbr
GOING	go	vvg
With	with	iw
the	the	at
advances	advance	nn2
discussed	discuss	vvn
above	above	rl
,	,	y
the	the	at
field	field	nn1
is	be	vbz
moving	move	vvg
into	into	ii
new	new	jj
areas	area	nn2
that	that	cst
promise	promise	vv0
significant	significant	jj
progress	progress	nn1
in	in	ii
identifying	identify	vvg
,	,	y
preventing	prevent	vvg
,	,	y
and	and	cc
treating	treat	vvg
addiction	addiction	nn1
.	.	y
Many	many	da2
key	key	jj
questions	question	nn2
remain	remain	vv0
.	.	y
What	what	ddq
neurobiological	neurobiological	jj
processes	process	nn2
(	(	y
system	system	nn1
,	,	y
cellular	cellular	jj
,	,	y
and	and	cc
molecular	molecular	jj
)	)	y
convey	convey	vv0
vulnerability	vulnerability	nn1
to	to	ii
the	the	at
transition	transition	nn1
from	from	ii
drug	drug	nn1
use	use	nn1_vv0
to	to	to
abuse	abuse	vvi
and	and	cc
addiction	addiction	nn1
,	,	y
with	with	iw
a	a	at1
particular	particular	jj
emphasis	emphasis	nn1
on	on	ii
adolescent	adolescent	jj_nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
How	how	rrq
do	do	vd0
environmental	environmental	jj
and	and	cc
genetic	genetic	jj
factors	factor	nn2
facilitate	facilitate	vv0
the	the	at
changes	change	nn2
in	in	ii
neurobiological	neurobiological	jj
processes	process	nn2
that	that	cst
convey	convey	vv0
vulnerability	vulnerability	nn1
to	to	ii
addiction--and		cc
protection	protection	nn1
from	from	ii
addiction	addiction	nn1
?	?	y
How	how	rrq
can	can	vm
the	the	at
brain	brain	nn1
best	best	rrt
"	"	y
recover	recover	vv0
"	"	y
to	to	to
eliminate	eliminate	vvi
abuse	abuse	nn1
and	and	cc
addiction	addiction	nn1
and	and	cc
to	to	to
eliminate	eliminate	vvi
relapse	relapse	nn1
(	(	y
behavioral	behavioral	jj_nn1
therapies	therapy	nn2
,	,	y
pharmacotherapies		nn2
)	)	y
?	?	y
<p>	<p>	y
Finally	finally	rr
,	,	y
while	while	cs
no	no	at
exact	exact	jj
marker	marker	nn1
necessarily	necessarily	rr
predicts	predict	vvz
addiction	addiction	nn1
,	,	y
two	two	mc
salient	salient	jj
changes	change	nn2
in	in	ii
imaging	image	vvg_nn1
in	in	ii_rp@
established	established	jj@
and	and	cc
unrecovered	unrecovered	jj
substance-dependent	substance-dependent	jj
individuals	individual	nn2
that	that	cst
cut	cut	vv0_vvd@_nn1
across	across	ii
different	different	jj
drugs	drug	nn2
are	be	vbr
decreases	decrease	nn2@
in	in	ii
orbitofrontal/prefrontal	orbitofrontal/prefrontal	jj_nn1
cortex	cortex	nn1
function	function	nn1
and	and	cc
decreases	decrease	vvz
in	in	ii
brain	brain	nn1
dopamine	dopamine	nn1_vv0
D2	d2	fo
receptors	receptor	nn2
.	.	y
No	no	xx
biochemical	biochemical	jj
markers	marker	nn2
are	be	vbr
sufficiently	sufficiently	rr
specific	specific	jj
to	to	to
predict	predict	vvi
a	a	at1
given	given	jj@
stage	stage	nn1
of	of	io
the	the	at
addiction	addiction	nn1
cycle	cycle	nn1
,	,	y
but	but	ccb
changes	change	nn2_vvz@
in	in	ii
certain	certain	jj
intermediate	intermediate	jj
early	early	jj
genes	gene	nn2
with	with	iw
chronic	chronic	jj
drug	drug	nn1
exposure	exposure	nn1
in	in	ii
animal	animal	nn1
models	model	nn2
show	show	vv0
promise	promise	nn1
of	of	io
long-term	long-term	jj
changes	change	nn2
in	in	ii
specific	specific	jj
brain	brain	nn1
regions	region	nn2
that	that	cst_dd1
may	may	vm
be	be	vbi
common	common	jj
to	to	ii
all	all	db
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
.	.	y
Although	although	cs
no	no	at
biological	biological	jj
markers	marker	nn2
of	of	io
substance	substance	nn1
abuse	abuse	nn1
disorders	disorder	nn2
are	be	vbr
on	on	ii
the	the	at
immediate	immediate	jj
horizon	horizon	nn1
,	,	y
many	many	da2
promising	promising	jj
and	and	cc
continually	continually	rr
evolving	evolve	vvg
biological	biological	jj
and	and	cc
neurobiological	neurobiological	jj
aspects	aspect	nn2
of	of	io
substance	substance	nn1
use	use	nn1_vv0
disorders	disorder	nn2
will	will	vm
eventually	eventually	rr
aid	aid	vvi
in	in	ii
the	the	at
specific	specific	jj
diagnoses	diagnosis	nn2
of	of	io
substance	substance	nn1
use	use	nn1_vv0
,	,	y
misuse	misuse	nn1_vv0@
,	,	y
and	and	cc
dependence	dependence	nn1
.	.	y
<p>	<p>	y
Much	much	rr_da1
needs	need	vvz
to	to	to
be	be	vbi
done	do	vdn
in	in	ii
the	the	at
area	area	nn1
of	of	io
molecular	molecular	jj
and	and	cc
biochemical	biochemical	jj
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
,	,	y
as	as	csa
seen	see	vvn
from	from	ii
this	this	dd1
brief	brief	jj
review	review	nn1
.	.	y
The	the	at
big	big	jj
disappointment	disappointment	nn1
to	to	ii
scientists	scientist	nn2
in	in	ii
this	this	dd1
field	field	nn1
is	be	vbz
that	that	cst_rg%_dd1
34	34	mc
years	year	nnt2
into	into	ii
the	the	at
modern	modern	jj
era	era	nn1
of	of	io
drug	drug	nn1
abuse	abuse	nn1
research	research	nn1
,	,	y
we	we	ppis2
still	still	rr
do	do	vd0
not	not	xx
have	have	vhi
a	a	at1
clear	clear	jj
understanding	understanding	nn1
of	of	io
the	the	at
cellular	cellular	jj
and	and	cc
molecular	molecular	jj
bases	base	nn2
of	of	io
the	the	at
development	development	nn1
and	and	cc
maintenance	maintenance	nn1
of	of	io
tile	tile	nn1
phenomena	phenomenon	nn2
of	of	io
addiction	addiction	nn1
,	,	y
such	such	ii21
as	as	ii22
tolerance	tolerance	nn1
,	,	y
physical	physical	jj
dependence	dependence	nn1
,	,	y
and	and	cc
psychic	psychic	jj
craving	craving	nn1@
.	.	y
The	the	at
progress	progress	nn1
in	in	ii
biochemical	biochemical	jj
approaches	approach	nn2
to	to	ii
our	our	appge
understanding	understanding	nn1
of	of	io
the	the	at
enzymes	enzyme	nn2
involved	involved	jj
in	in	ii
signal	signal	nn1
transduction	transduction	nn1
pathways	pathway	nn2
also	also	rr
has	have	vhz
been	be	vbn
quite	quite	rg
impressive	impressive	jj
.	.	y
Additional	additional	jj
technologies	technology	nn2
,	,	y
such	such	ii21
as	as	ii22
imaging	imaging	nn1_vvg
and	and	cc
electrophysiology	electrophysiology	nn1
,	,	y
which	which	ddq
are	be	vbr
not	not	xx
discussed	discuss	vvn
here	here	rl
,	,	y
have	have	vh0
progressed	progress	vvn
rapidly	rapidly	rr
as	as	rr21_rg
well	well	rr22_rr
.	.	y
We	we	ppis2
feel	feel	vv0
cautiously	cautiously	rr
optimistic	optimistic	jj
that	that	cst
the	the	at
molecular	molecular	jj
basis	basis	nn1
of	of	io
some	some	dd
of	of	io
the	the	at
events	event	nn2
that	that	cst
lead	lead	vv0_nn1
to	to	ii
drug	drug	nn1
addiction	addiction	nn1
and	and	cc
abuse	abuse	nn1
will	will	vm
be	be	vbi
discovered	discover	vvn@
within	within	ii
the	the	at
next	next	md
5	5	mc
to	to	ii
10	10	mc
years	year	nnt2
.	.	y
What	what	ddq
is	be	vbz
the	the	at
molecular	molecular	jj
basis	basis	nn1
of	of	io
tolerance	tolerance	nn1
?	?	y
Of	of	io
dependence	dependence	nn1
?	?	y
What	what	ddq
alterations	alteration	nn2
in	in	ii
the	the	at
brain	brain	nn1
cause	cause	nn1_vv0
craving	crave	vvg
for	for	if
abused	abused	jj@
drugs	drug	nn2
to	to	to
increase	increase	vvi
greatly	greatly	rr
,	,	y
in	in	ii
some	some	dd
persons	person	nn2
who	who	pnqs
use	use	vv0
drugs	drug	nn2
casually	casually	rr
and	and	cc
not	not	xx
in	in	ii
others	others	nn2
?	?	y
What	what	ddq
is	be	vbz
the	the	at
genetic	genetic	jj
basis	basis	nn1
for	for	if
these	these	dd2
individual	individual	jj
differences	difference	nn2
?	?	y
What	what	ddq
is	be	vbz
the	the	at
biochemical	biochemical	jj
basis	basis	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
Which	which	ddq
parts	part	nn2
of	of	io
the	the	at
pathways	pathway	nn2
that	that	cst
are	be	vbr
set	set	vvn
into	into	ii
motion	motion	nn1
by	by	ii
the	the	at
consumption	consumption	nn1
of	of	io
abused	abused	jj@
drugs	drug	nn2
can	can	vm
we	we	ppis2
intervene	intervene	vvi
to	to	to
block	block	vvi
the	the	at
development	development	nn1
of	of	io
addiction	addiction	nn1
?	?	y
These	these	dd2
are	be	vbr
some	some	dd
of	of	io
the	the	at
questions	question	nn2
that	that	cst_dd1
should	should	vm
be	be	vbi
answered	answer	vvn
,	,	y
'	'	ge_"@
using	use	vvg
the	the	at
highly	highly	rr
sophisticated	sophisticated	jj
technologies	technology	nn2
currently	currently	rr
available	available	jj
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
SUMMARY	summary	nn1
AND	and	cc
CONCLUSIONS	conclusion	nn2
The	the	at
advances	advance	nn2
in	in	ii
the	the	at
neurobiology	neurobiology	nn1
of	of	io
addiction	addiction	nn1
are	be	vbr
examined	examine	vvn
here	here	rl
from	from	ii
two	two	mc
domains	domain	nn2
.	.	y
First	first	md
,	,	y
a	a	at1
heuristic	heuristic	jj
framework	framework	nn1
is	be	vbz
provided	provide	vvn
of	of	io
the	the	at
neurocircuitry	neurocircuitry	nn1
of	of	io
addiction	addiction	nn1
.	.	y
Second	second	md
,	,	y
advances	advance	vvz_nn2
in	in	ii
the	the	at
molecular	molecular	jj
biology	biology	nn1
of	of	io
the	the	at
opioid	opioid	jj_nn1
system	system	nn1
demonstrate	demonstrate	vv0
the	the	at
tremendous	tremendous	jj
advances	advance	nn2
we	we	ppis2
have	have	vh0
made	make	vvn
in	in	ii
our	our	appge
understanding	understanding	nn1
of	of	io
the	the	at
molecular	molecular	jj
basis	basis	nn1
'	'	ge
of	of	io
the	the	at
action	action	nn1
of	of	io
the	the	at
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
.	.	y
A	a	at1_zz1
conceptual	conceptual	jj
structure	structure	nn1
for	for	if
drug	drug	nn1
addiction	addiction	nn1
that	that	cst_dd1
focuses	focus	vvz
on	on	ii_rp@
changes	change	nn2
in	in	ii
reward	reward	nn1
system	system	nn1
function	function	nn1_vv0@
that	that	cst_dd1
lead	lead	vv0_nn1
to	to	ii
excessive	excessive	jj
drug	drug	nn1
intake	intake	nn1
provides	provide	vvz
a	a	at1
framework	framework	nn1
with	with	iw
which	which	ddq
to	to	to
identify	identify	vvi
the	the	at
neurobiological	neurobiological	jj
and	and	cc
neuroadaptive	neuroadaptive	jj
mechanisms	mechanism	nn2
involved	involved	jj
in	in	ii
the	the	at
neurobiology	neurobiology	nn1
of	of	io
drug	drug	nn1
addiction	addiction	nn1
.	.	y
The	the	at
neurochemical	neurochemical	jj
systems	system	nn2
implicated	implicate	vvd_vvn@
in	in	ii
the	the	at
acute	acute	jj
reinforcing	reinforcing	jj@_vvg
effects	effect	nn2
of	of	io
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
include	include	vv0
key	key	jj
elements	element	nn2
of	of	io
the	the	at
basal	basal	jj
forebrain	forebrain	nn1
linked	link	vvn
by	by	ii
the	the	at
mesocorticolimbic	mesocorticolimbic	jj
dopamine	dopamine	nn1
system	system	nn1
,	,	y
which	which	ddq
include	include	vv0
dopamine-dependent	dopamine-dependent	jj
and	and	cc
-independent	-independent	jj
actions	action	nn2
via	via	ii
dopamine	dopamine	nn1
,	,	y
opioid	opioid	jj_nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
effects	effect	nn2
of	of	io
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
.	.	y
Neuroadaptive	neuroadaptive	jj
changes	change	nn2
in	in	ii
the	the	at
brain	brain	nn1
reward	reward	nn1
system	system	nn1
during	during	ii
the	the	at
development	development	nn1
of	of	io
dependence	dependence	nn1
include	include	vv0
decreases	decrease	nn2@_vvz
in	in	ii
these	these	dd2
same	same	da
drug	drug	nn1
reward	reward	nn1_vv0@
neurochemical	neurochemical	jj
systems	system	nn2
and	and	cc
recruitment	recruitment	nn1
of	of	io
brain	brain	nn1
stress	stress	nn1
systems	system	nn2
(	(	y
CRF	crf	np1
and	and	cc
norepinephrine	norepinephrine	nn1_jj
;	;	y
"	"	y
dark	dark	jj_nn1
side	side	nn1
"	"	y
)	)	y
and	and	cc
dysregulation	dysregulation	nn1
of	of	io
brain	brain	nn1
anti-stress	anti-stress	nn1_jj
systems	system	nn2
(	(	y
NPY	npy	np1
)	)	y
in	in	ii
the	the	at
extended	extended	jj@
amygdala	amygdala	nn1
that	that	cst
provide	provide	vv0
the	the	at
negative	negative	jj
motivational	motivational	jj
state	state	nn1
associated	associate	vvn
with	with	iw
drug	drug	nn1
abstinence	abstinence	nn1
(	(	y
Koob	koob	np1
&;		null
Le	le	np1
Moal	moal	np1
,	,	y
2008	2008	mc
)	)	y
.	.	y
Neurochemical	neurochemical	jj
systems	system	nn2
have	have	vh0
been	be	vbn
implicated	implicate	vvn@
in	in	ii
animal	animal	nn1
models	model	nn2
of	of	io
relapse	relapse	nn1
,	,	y
including	including	ii_vvg@
dopamine	dopamine	nn1
,	,	y
opioid	opioid	jj_nn1
peptide	peptide	nn1
,	,	y
and	and	cc
glutamate	glutamate	nn1
,	,	y
and	and	cc
in	in	ii
drug-	drug-	nn1_jj
and	and	cc
cue-induced	cue-induced	jj_nn1
relapse	relapse	nn1
in	in	ii
prefrontal	prefrontal	jj
cortical	cortical	jj
and	and	cc
basolateral	basolateral	jj_nn1
amygdala	amygdala	nn1
projections	projection	nn2
to	to	ii
the	the	at
basal	basal	jj
forebrain	forebrain	nn1
.	.	y
The	the	at
brain	brain	nn1
stress	stress	nn1
systems	system	nn2
in	in	ii
the	the	at
extended	extended	jj@
amygdala	amygdala	nn1
are	be	vbr
directly	directly	rr
implicated	implicate	vvn
in	in	ii
stress-induced	stress-induced	jj_nn1
relapse	relapse	nn1
.	.	y
<p>	<p>	y
Gaps	gap	nn2
in	in	ii
our	our	appge
knowledge	knowledge	nn1
center	center	nn1
on	on	ii
identifying	identify	vvg
the	the	at
molecular	molecular	jj
changes	change	nn2
that	that	cst
contribute	contribute	vv0
to	to	ii
the	the	at
neuroadaptations		nn2
within	within	ii
specific	specific	jj
motivationally	motivationally	rr
relevant	relevant	jj
neurocircuits		nn2
associated	associate	vvn
with	with	iw
the	the	at
transition	transition	nn1
to	to	ii
dependence	dependence	nn1
,	,	y
motivational	motivational	jj
withdrawal	withdrawal	nn1
,	,	y
protracted	protracted	jj
abstinence	abstinence	nn1
,	,	y
and	and	cc
vulnerability	vulnerability	nn1
to	to	to
relapse	relapse	vvi
.	.	y
Nevertheless	nevertheless	rr
,	,	y
the	the	at
identification	identification	nn1
of	of	io
specific	specific	jj
neurochemical	neurochemical	jj
systems	system	nn2
within	within	ii
specific	specific	jj
components	component	nn2
of	of	io
the	the	at
brain	brain	nn1
reward	reward	nn1
and	and	cc
stress	stress	nn1_vv0@
systems	system	nn2
that	that	cst
have	have	vh0
an	a	at1
important	important	jj
role	role	nn1
in	in	ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
solid	solid	jj
foundation	foundation	nn1
for	for	if
bridging	bridge	vvg
the	the	at
molecular/		jj
cellular	cellular	jj
gap	gap	nn1
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
ACKNOWLEDGEMENTS	acknowledgement	nn2
Research	research	nn1
was	be	vbdz
supported	support	vvn
by	by	ii
National	national	jj
Institutes	institute	nn2
of	of	io
Health	health	nn1
grants	grant	vvz_nn2
AA06420		fo
and	and	cc
AA08459		fo
from	from	ii
the	the	at
National	national	jj
Institute	institute	nn1
on	on	ii
Alcohol	alcohol	nn1
Abuse	abuse	nn1
and	and	cc
Alcoholism	alcoholism	nn1
,	,	y
DA04043		fo
and	and	cc
DA04398		fo
from	from	ii
the	the	at
National	national	jj
Institute	institute	nn1
on	on	ii
Drug	drug	nn1
Abuse	abuse	nn1
,	,	y
and	and	cc
DK26741		fo
from	from	ii
the	the	at
National	national	jj
Institute	institute	nn1
on	on	ii
Diabetes	diabetes	nn1
and	and	cc
Digestive	digestive	jj
and	and	cc
Kidney	kidney	nn1
Diseases	disease	nn2
.	.	y
Research	research	vv0@_nn1
also	also	rr
was	be	vbdz
supported	support	vvn
by	by	ii
the	the	at
Pearson	pearson	np1
Center	center	nn1
for	for	if
Alcoholism	alcoholism	nn1
and	and	cc
Addiction	addiction	npx
Research	research	nn1
at	at	ii
The	the	at
Scripps	scripps	np1_nn2
Research	research	nn1_vv0@
Institute	institute	nn1
.	.	y
Dr.	dr	nnb
Simon	simon	np1
gratefully	gratefully	rr
acknowledges	acknowledge	vvz
the	the	at
support	support	nn1
of	of	io
NIDA	nida	nn1_np1
for	for	if
over	over	rg
40	40	mc
years	year	nnt2
(	(	y
DA00017		fo
)	)	y
,	,	y
the	the	at
former	former	da
KO5	ko5	fo
(	(	y
DA	da	fu
00364	00364	mc
)	)	y
,	,	y
which	which	ddq
paid	pay	vvd
a	a	at1
portion	portion	nn1
of	of	io
his	his	appge
salary	salary	nn1
for	for	if
5	5	mc
years	year	nnt2
,	,	y
as	as	ii31
well	well	ii32
as	as	ii33
a	a	at1
Training	training	nn1
Grant	grant	np1_nn1@
(	(	y
T32-DA07254		nn1_jj
)	)	y
.	.	y
He	he	pphs1
also	also	rr
wishes	wish	vvz
to	to	to
pay	pay	vvi
tribute	tribute	nn1
to	to	ii
the	the	at
many	many	da2
students	student	nn2
,	,	y
postdoctoral	postdoctoral	jj_nn1
fellows	fellow	nn2
,	,	y
and	and	cc
visiting	visiting	jj_vvg
professors	professor	nn2
he	he	pphs1
has	have	vhz
been	be	vbn
privileged	privileged	jj_vvn%
to	to	to
train	train	vvi
and	and	cc
collaborate	collaborate	vvi
with	with	iw
,	,	y
and	and	cc
whose	whose	ddqge
input	input	nn1
and	and	cc
hard	hard	jj_rr
work	work	nn1
have	have	vh0
been	be	vbn
extremely	extremely	rr
important	important	jj
to	to	ii
the	the	at
success	success	nn1
of	of	io
his	his	appge
laboratory	laboratory	nn1
.	.	y
The	the	at
authors	author	nn2
gratefully	gratefully	rr
acknowledge	acknowledge	vv0
the	the	at
editorial	editorial	nn1_jj
and	and	cc
research	research	nn1_vv0@
assistance	assistance	nn1
of	of	io
Mr.	mr	nnb
Michael	michael	np1
A.	a	zz
Arends	arends	np1_vvz_nn2
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
Table	table	nn1
1	1	mc1
Neurotransmitters	neurotransmitter	vvz_np1
Implicated	implicated	jj_vvd@
in	in	ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
table	table	nn1
L	l	zz1_np1@
:	:	y
Table	table	nn1
2	2	mc
Neurotransmitters	neurotransmitter	nn2_np1_vvz
Implicated	implicate	vvd@_jj
in	in	ii
the	the	at
Motivational	motivational	jj
Effects	effect	nn2
of	of	io
Withdrawal	withdrawal	nn1
from	from	ii
Drugs	drug	nn2
of	of	io
Abuse	abuse	nn1
pre-formatted		zz
table	table	nn1
L	l	zz1_np1@
:	:	y
Table	table	nn1
3	3	mc
Endogenous	endogenous	jj_np1
Opioid	opioid	jj_nn1_np1
Peptides	peptide	nn2
pre-formatted		zz
table	table	nn1
L	l	zz1_np1@
:	:	y
Table	table	nn1
4	4	mc
List	list	nn1
of	of	io
Techniques	technique	nn2
Derived	derive	vvn
from	from	ii
DNA	dna	nn1
Cloning	cloning	nn1_vvg@
pre-formatted		zz
table	table	nn1
DIAGRAM	diagram	nn1
:	:	y
Figure	figure	nn1_vv0%
1	1	mc1
.	.	y
Diagram	diagram	nn1
describing	describe	vvg
the	the	at
addiction	addiction	nn1
**33;5888;TOOLONG		fo
,	,	y
binge/intoxication	binge/intoxication	nn1
,	,	y
and	and	cc
withdrawal/negative	withdrawal/negative	nn1
affect--from	affect--from	ii
a	a	at1
psychiatric	psychiatric	jj
perspective	perspective	nn1
with	with	iw
the	the	at
different	different	jj
criteria	criteria	nn2
for	for	if
substance	substance	nn1
dependence	dependence	nn1
incorporated	incorporate	vvn
from	from	ii
the	the	at
DSM-IV	dsm-iv	jj
.	.	y
<p>	<p>	y
DIAGRAM	diagram	nn1
:	:	y
Figure	figure	nn1
2	2	mc
.	.	y
Early	early	jj
neurocircuitry	neurocircuitry	nn1
diagram	diagram	nn1
of	of	io
drug	drug	nn1
reward	reward	nn1
for	for	if
opiates	opiate	nn2
(	(	y
Wise	wise	np1
,	,	y
1980	1980	mc
)	)	y
.	.	y
"	"	y
Suggested	suggested	jj@_vvn
sites	site	nn2
of	of	io
potential	potential	jj_nn1
interaction	interaction	nn1
of	of	io
opiates	opiate	nn2
with	with	iw
brain	brain	nn1
reward	reward	nn1
circuitry	circuitry	nn1
.	.	y
Opiate	opiate	vv0_nn1
receptor	receptor	nn1
fields	field	nn2
are	be	vbr
shaded	shade	vvn@_jj
in	in	ii
the	the	at
region	region	nn1
of	of	io
the	the	at
striatal	striatal	jj
dopamine	dopamine	nn1
terminal	terminal	nn1_jj
field	field	nn1
,	,	y
the	the	at
tegmental	tegmental	jj
dopamine	dopamine	nn1
cell	cell	nn1
region	region	nn1
,	,	y
and	and	cc
the	the	at
region	region	nn1
of	of	io
the	the	at
locus	locus	nn1
coeruleus	coeruleus	nn
,	,	y
which	which	ddq
is	be	vbz
thought	think	vvn
to	to	to
inhibit	inhibit	vvi
reward	reward	nn1
circuitry	circuitry	nn1
,	,	y
perhaps	perhaps	rr
by	by	ii
an	a	at1
inhibitory	inhibitory	jj
synapse	synapse	nn1
on	on	ii
the	the	at
dopamine	dopamine	nn1
cells	cell	nn2
themselves	themselves	ppx2
.	.	y
Opiates	opiate	nn2_np1@
inhibit	inhibit	vv0_nn1
locus	locus	nn1
coeruleus	coeruleus	nn
firing	fire	vvg_nn1
;	;	y
their	their	appge
actions	action	nn2
in	in	ii
the	the	at
tegmentum	tegmentum	nn1
and	and	cc
striatum	striatum	nn1
are	be	vbr
not	not	xx
yet	yet	rr
understood	understand	vvn_vvd
,	,	y
and	and	cc
may	may	vm
be	be	vbi
either	either	rr
pre-	pre-	jj
or	or	cc
post-synaptic	post-synaptic	jj_nn1@
in	in	ii
either	either	dd1
region	region	nn1
.	.	y
Thus	thus	rr
,	,	y
opiates	opiate	nn2_vvz
may	may	vm
act	act	vvi
on	on	rp@
,	,	y
or	or	cc
either	either	rr
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
reward	reward	nn1
function	function	nn1
.	.	y
"	"	y
Taken	take	vvn
with	with	iw
permission	permission	nn1
from	from	ii
Wise	wise	np1_jj
,	,	y
1980	1980	mc
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
REFERENCES	reference	nn2_vvz@
--		zz
Evans	evans	np1
,	,	y
C.	c	np1_zz1@
,	,	y
Keith	keith	np1
,	,	y
D.	d	np1
,	,	y
Morrison	morrison	np1
,	,	y
H.	h	np1
,	,	y
Magendzo	magendzo	np1_nn1
,	,	y
K.	k	np1
,	,	y
&;		null
Edwards	edwards	np1
,	,	y
R.	xx_r	np1
1992	1992	mc
Cloning	cloning	nn1
of	of	io
a	a	at1
delta-opioid	delta-opioid	jj_nn1
receptor	receptor	nn1
by	by	ii
functional	functional	jj
expression	expression	nn1
.	.	y
Science	science	nn1
,	,	y
258	258	mc
,	,	y
1952-1955		mcmc
.	.	y
<p>	<p>	y
--		zz
Gioannini	gioannini	nn1_np1_nn2@
,	,	y
T.L.	tl	np1
,	,	y
Fan	fan	vv0_nn1
,	,	y
L.Q.	l.q	np1
,	,	y
Hyde	hyde	np1
,	,	y
L.	l	np1
,	,	y
Ofri	ofri	np1_nn1
,	,	y
D.	d	np1
,	,	y
Yao	yao	np1
,	,	y
Y.	y	np1
,	,	y
Hiller	hiller	nn1_np1@
,	,	y
J.M.	jm	np1
,	,	y
&;		null
Simon	simon	np1
,	,	y
E.J.	e.j	np1
1993	1993	mc
Reconstitution	reconstitution	nn1
of	of	io
a	a	at1
purified	purified	jj@
mu-opioid	mu-opioid	jj_nn1
binding	binding	jj_vvg
protein	protein	nn1
in	in	ii
liposomes	liposomes	nn2
:	:	y
Selective	selective	jj
,	,	y
high	high	jj
affinity	affinity	nn1
,	,	y
GTP-gamma	gtp-gamma	jj
S-sensitive	s-sensitive	jj
mu-opioid	mu-opioid	jj_nn1
agonist	agonist	nn1
binding	binding	nn1@_vvg
is	be	vbz
restored	restore	vvn_jj
.	.	y
Biochemical	biochemical	jj_np1@
and	and	cc
Biophysical	biophysical	jj_np1
Research	research	nn1
Communications	communication	nn2
,	,	y
194	194	mc
,	,	y
901-908		mcmc
.	.	y
<p>	<p>	y
--		zz
Gioannini	gioannini	nn1_np1_nn2@
,	,	y
T.L.	tl	np1
,	,	y
Howard	howard	np1
,	,	y
A.D.	ad	ra
,	,	y
Hiller	hiller	nn1_np1@
,	,	y
J.M.	jm	np1
,	,	y
&;		null
Simon	simon	np1
,	,	y
E.J.	e.j	np1
1985	1985	mc
Purification	purification	nn1
of	of	io
an	a	at1
active	active	jj
opioid	opioid	jj_nn1
binding	binding	jj_vvg
protein	protein	nn1
from	from	ii
bovine	bovine	jj
striatum	striatum	nn1
.	.	y
Journal	journal	nn1
of	of	io
Biological	biological	jj
Chemistry	chemistry	nn1
,	,	y
260	260	mc
,	,	y
15117-15121		mcmc
.	.	y
<p>	<p>	y
--		zz
Heilig	heilig	nn1_np1
,	,	y
M.	m	nn1
,	,	y
Koob	koob	np1
,	,	y
G.F.	gf	np1
,	,	y
Ekman	ekman	np1_nn1
,	,	y
R.	xx_r	np1
,	,	y
&;		null
Britton	britton	np1
,	,	y
K.T.	kt	np1
1994	1994	mc
Corticotropin-releasing	corticotropin-releasing	jj
factor	factor	nn1
and	and	cc
neuropeptide	neuropeptide	vv0_nn1
Y	y	zz1
:	:	y
Role	role	nn1
in	in	ii
emotional	emotional	jj
integration	integration	nn1
.	.	y
Trends	trend	nn2
in	in	ii
Neurosciences	neuroscience	np2_nn2@
,	,	y
17	17	mc
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
Koob	koob	np1
,	,	y
G.F.	gf	np1
2004	2004	mc
Corticotropin-releasing	corticotropin-releasing	jj
factor	factor	nn1
in	in	ii
brain	brain	nn1
:	:	y
A	a	at1@_zz1
role	role	nn1
in	in	ii
activation	activation	nn1
,	,	y
arousal	arousal	nn1
,	,	y
and	and	cc
affect	affect	vv0_nn1
regulation	regulation	nn1
.	.	y
Journal	journal	nn1
of	of	io
Pharmacology	pharmacology	np1_nn1
and	and	cc
Experimental	experimental	jj
Therapeutics	therapeutics	nn1
,	,	y
311,427-440		mcmc
.	.	y
<p>	<p>	y
--		zz
Kieffer	kieffer	nn1_np1
,	,	y
B.	b	np1
,	,	y
Befort		np1_vv0_nn1
,	,	y
K.	k	np1
,	,	y
Ruff	ruff	nn1
,	,	y
C.	c	np1_zz1@
,	,	y
&;		null
Hirth	hirth	np1_nn1
,	,	y
C.	c	np1_zz1@
1992	1992	mc
The	the	at
delta-opioid	delta-opioid	jj_nn1
receptor	receptor	nn1
:	:	y
Isolation	isolation	nn1
of	of	io
a	a	at1
cDNA	cdna	nn1
by	by	ii
expression	expression	nn1
cloning	cloning	nn1
and	and	cc
pharmacological	pharmacological	jj
characterization	characterization	nn1
.	.	y
Proceedings	proceedings	nn2
of	of	io
the	the	at
National	national	jj
Academy	academy	nn1
of	of	io
Sciences	science	nn2
USA	usa	np1
,	,	y
89	89	mc
,	,	y
12048-12052		mcmc
.	.	y
<p>	<p>	y
--		zz
Kieffer	kieffer	nn1_np1
,	,	y
B.	b	np1
,	,	y
&;		null
Gaveriaux-Ruff		np1
,	,	y
C.	c	np1_zz1@
2002	2002	mc
Exploring	explore	vvg
the	the	at
opioid	opioid	jj_nn1
system	system	nn1
by	by	ii
gene	gene	nn1
knockout	knockout	nn1
.	.	y
Progress	progress	nn1_vv0@
in	in	ii
Neurobiology	neurobiology	np1_nn1
,	,	y
66	66	mc
,	,	y
285-306		mcmc
.	.	y
<p>	<p>	y
--		zz
Koob	koob	np1_nn1@
,	,	y
G.F.	gf	np1
1992	1992	mc
Drugs	drug	nn2
of	of	io
abuse	abuse	nn1
:	:	y
Anatomy	anatomy	nn1
,	,	y
pharmacology	pharmacology	nn1
,	,	y
and	and	cc
function	function	nn1
of	of	io
reward	reward	nn1
pathways	pathway	nn2
.	.	y
Trends	trend	nn2
in	in	ii
Pharmacological	pharmacological	jj_np1
Sciences	science	nn2
,	,	y
13	13	mc
,	,	y
177-184		mcmc
<p>	<p>	y
--		zz
Koob	koob	np1_nn1@
,	,	y
G.F.	gf	np1
2003	2003	mc
Neuroadaptive	neuroadaptive	jj
mechanisms	mechanism	nn2
of	of	io
addiction	addiction	nn1
:	:	y
Studies	study	nn2
on	on	ii
the	the	at
extended	extended	jj@
amygdala	amygdala	nn1
.	.	y
European	european	jj
Neuropsychopharmacology	neuropsychopharmacology	nn1_np1
,	,	y
13	13	mc
,	,	y
442-452		mcmc
.	.	y
<p>	<p>	y
--		zz
Koob	koob	np1_nn1@
,	,	y
G.F.	gf	np1
2004	2004	mc
Allostatic	allostatic	jj
view	view	nn1
of	of	io
motivation	motivation	nn1
:	:	y
Implications	implication	nn2
for	for	if
psychopathology	psychopathology	nn1
.	.	y
In	in	ii
R.A.	ra	np1
Bevins	bevins	np1
&;		null
M.T	m.t	nnl1
.	.	y
Bardo	bardo	np1@_nn1
(	(	y
Eds	ed	nn2
.	.	y
)	)	y
,	,	y
Motivational	motivational	jj
factors	factor	nn2
in	in	ii
the	the	at
etiology	etiology	nn1
of	of	io
drug	drug	nn1
abuse	abuse	nn1
(	(	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
)	)	y
(	(	y
pp.	pp	nnu2
1-18	1-18	mcmc
)	)	y
.	.	y
Lincoln	lincoln	np1
NE	ne	nd1
:	:	y
University	university	nn1
of	of	io
Nebraska	nebraska	np1
Press	press	nn1_vv0
.	.	y
<p>	<p>	y
--		zz
Koob	koob	np1_nn1@
,	,	y
G.F.	gf	np1
2008	2008	mc
A	a	zz1_at1@
role	role	nn1
for	for	if
brain	brain	nn1
stress	stress	nn1
systems	system	nn2
in	in	ii
addiction	addiction	nn1
.	.	y
Neuron	neuron	nn1_np1@
,	,	y
59	59	mc
,	,	y
11-34	11-34	mcmc
.	.	y
<p>	<p>	y
--		zz
Koob	koob	np1_nn1@
,	,	y
G.F.	gf	np1
,	,	y
&;		null
Le	le	np1
Moal	moal	np1
,	,	y
M.	m	nn1
2001	2001	mc
Drug	drug	nn1
addiction	addiction	nn1
,	,	y
dysregulation	dysregulation	nn1
of	of	io
reward	reward	nn1
,	,	y
and	and	cc
allostasis	allostasis	nn1
.	.	y
Neuropsychopharmacology	neuropsychopharmacology	nn1_np1@
,	,	y
24	24	mc
,	,	y
97-129		mcmc
.	.	y
<p>	<p>	y
--		zz
Koob	koob	np1_nn1@
,	,	y
G.F.	gf	np1
,	,	y
&;		null
Le	le	np1
Moal	moal	np1
,	,	y
M.	m	nn1
2005	2005	mc
Plasticity	plasticity	nn1
of	of	io
reward	reward	nn1
neurocircuitry	neurocircuitry	nn1
and	and	cc
the	the	at
'	'	ge
dark	dark	jj_nn1
side	side	nn1
'	'	ge
of	of	io
drug	drug	nn1
addiction	addiction	nn1
.	.	y
Nature	nature	nn1
Neuroscience	neuroscience	np1_nn1@
,	,	y
8	8	mc
,	,	y
1442-1444		mcmc
.	.	y
<p>	<p>	y
--		zz
Koob	koob	np1_nn1@
,	,	y
G.F.	gf	np1
,	,	y
&;		null
Le	le	np1
Moal	moal	np1
,	,	y
M.	m	nn1
2006	2006	mc
Neurobiology	neurobiology	nn1
of	of	io
addiction	addiction	nn1
.	.	y
London	london	np1
:	:	y
Academic	academic	jj
Press	press	nn1
.	.	y
<p>	<p>	y
--		zz
Koob	koob	np1_nn1@
,	,	y
G.F.	gf	np1
,	,	y
&;		null
Le	le	np1
Moal	moal	np1
,	,	y
M.	m	nn1
2008	2008	mc
Addiction	addiction	npx
and	and	cc
the	the	at
brain	brain	nn1
antireward	antireward	jj
system	system	nn1
.	.	y
Annual	annual	jj
Review	review	nn1
of	of	io
Psychology	psychology	nn1
,	,	y
59	59	mc
,	,	y
29-53	29-53	mcmc
.	.	y
<p>	<p>	y
--		zz
Koob	koob	np1_nn1@
,	,	y
G.F.	gf	np1
,	,	y
Sanna	sanna	np1
,	,	y
P.P.	pp	nn1
,	,	y
&;		null
Bloom	bloom	np1
,	,	y
F.E.	f.e	fo
1998	1998	mc
Neuroscience	neuroscience	nn1@_np1
of	of	io
addiction	addiction	nn1
.	.	y
Neuron	neuron	nn1_np1@
,	,	y
21,467-476		mcmc
.	.	y
<p>	<p>	y
--		zz
Kramer	kramer	nn1_np1
,	,	y
H.K.	hk	np1
,	,	y
Andria	andria	np1
,	,	y
M.L.	m.l	nnu
,	,	y
Esposito	esposito	np1_nn1
,	,	y
D.H.	d.h	np1
,	,	y
&;		null
Simon	simon	np1
,	,	y
E.J.	e.j	np1
2000	2000	mc
Tyrosine	tyrosine	np1
phosphorylation	phosphorylation	nn1
of	of	io
the	the	at
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
kinase	kinase	nn1
activation	activation	nn1
and	and	cc
receptor	receptor	nn1
internalization	internalization	nn1
.	.	y
Biochemical	biochemical	jj_np1@
Pharmacology	pharmacology	nn1_np1
,	,	y
60	60	mc
,	,	y
781-792		mcmc
.	.	y
<p>	<p>	y
--		zz
McFarland	mcfarland	np1
,	,	y
K.	k	np1
,	,	y
&;		null
Kalivas	kalivas	np2_nn2@
,	,	y
P.W	pw	np1
.	.	y
2001	2001	mc
The	the	at
circuitry	circuitry	nn1
mediating	mediate	vvg
cocaine-induced	cocaine-induced	jj_nn1
reinstatement	reinstatement	nn1
of	of	io
drug-seeking	drug-seeking	jj_nn1
behavior	behavior	nn1
.	.	y
Journal	journal	nn1
of	of	io
Neuroscience	neuroscience	np1
,	,	y
21	21	mc
,	,	y
8655-8663		mcmc
.	.	y
<p>	<p>	y
--		zz
Noda	noda	np1_nn1@
,	,	y
M.	m	nn1
,	,	y
Teranishi		np1_nn1
,	,	y
Y.	y	np1
,	,	y
Takahashi	takahashi	np1_nn1
,	,	y
H.	h	np1
,	,	y
Toyosato		np1_nn1
,	,	y
M.	m	nn1
,	,	y
Notake		np1
,	,	y
M.	m	nn1
,	,	y
Nakanishi	nakanishi	np1_nn1
,	,	y
S.	s	np1
,	,	y
&;		null
Numa	numa	np1
,	,	y
S.	s	np1
1982	1982	mc
Isolation	isolation	nn1
and	and	cc
structural	structural	jj
organization	organization	nn1
of	of	io
the	the	at
human	human	jj_nn1
preproenkephalin	preproenkephalin	nn1
gene	gene	nn1
.	.	y
Nature	nature	nn1
,	,	y
297	297	mc
,	,	y
431-434		mcmc
.	.	y
<p>	<p>	y
--		zz
Pak	pak	np1_nn1@
,	,	y
Y.	y	np1
,	,	y
O'Dowd	o'dowd	np1
,	,	y
B.F.	bf	np1
,	,	y
Wang	wang	np1
,	,	y
J.B.	jb	np1
,	,	y
&;		null
George	george	np1
,	,	y
S.R.	s.r	nna
1999	1999	mc
Agonist-induced	agonist-induced	jj_nn1
,	,	y
G	g	zz1
protein-dependent	protein-dependent	jj
and	and	cc
-independent	-independent	jj
down-regulation	down-regulation	nn1
of	of	io
the	the	at
mu	mu	nn1
opioid	opioid	nn1_jj
receptor	receptor	nn1
.	.	y
The	the	at
receptor	receptor	nn1
is	be	vbz
a	a	at1
direct	direct	jj
substrate	substrate	nn1
for	for	if
protein	protein	nn1
tyrosine	tyrosine	nn1_vv0
kinase	kinase	nn1
.	.	y
Journal	journal	nn1
of	of	io
Biological	biological	jj
Chemistry	chemistry	nn1
,	,	y
2	2	mc
74	74	mc
,	,	y
27610-27616		mcmc
.	.	y
<p>	<p>	y
--		zz
Pert	pert	jj
,	,	y
C.B.	cb	np1
,	,	y
&;		null
Snyder	snyder	np1_vv0_nn1
,	,	y
S.H	s.h	np1
.	.	y
1973	1973	mc
Opiate	opiate	np1_nn1_vv0
receptor	receptor	nn1
:	:	y
Demonstration	demonstration	nn1
in	in	ii
nervous	nervous	jj
tissue	tissue	nn1
.	.	y
Science	science	nn1
,	,	y
179	179	mc
,	,	y
1011-1014		mcmc
.	.	y
<p>	<p>	y
--		zz
Schiffer	schiffer	np1
,	,	y
C.A.	ca	np1
2007	2007	mc
BCR-ABL	bcr-abl	jj
tyrosine	tyrosine	nn1
kinase	kinase	nn1
inhibitors	inhibitor	nn2
for	for	if
chronic	chronic	jj
myelogenous	myelogenous	jj
leukemia	leukemia	nn1
.	.	y
New	new	np1
England	england	np1
Journal	journal	nn1
of	of	io
Medicine	medicine	nn1
,	,	y
357	357	mc
,	,	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
U.	u	np1
,	,	y
Lu	lu	np1_nn1
,	,	y
L.	l	np1
,	,	y
De	de	np1
Wit	wit	nn1
,	,	y
H.	h	np1
,	,	y
&;		null
Stewart	stewart	np1
,	,	y
J.	xx_j	np1
2003	2003	mc
The	the	at
reinstatement	reinstatement	nn1
model	model	nn1
of	of	io
drug	drug	nn1
relapse	relapse	nn1_vv0
:	:	y
History	history	nn1
,	,	y
methodology	methodology	nn1
and	and	cc
major	major	jj
findings	finding	nn2
.	.	y
Psychopharmacology	psychopharmacology	nn1_np1@
,	,	y
168	168	mc
,	,	y
3-20	3-20	mcmc
.	.	y
<p>	<p>	y
--		zz
Shippenberg		np1
,	,	y
T.S.	t.s	np2
,	,	y
&;		null
Koob	koob	np1
,	,	y
G.F.	gf	np1
2002	2002	mc
Recent	recent	jj
advances	advance	nn2
in	in	ii
animal	animal	nn1
models	model	nn2
of	of	io
drug	drug	nn1
addiction	addiction	nn1
and	and	cc
alcoholism	alcoholism	nn1
.	.	y
In	in	ii
K.L.	kl	np1
Davis	davis	np1
,	,	y
D.	d	np1
Charney	charney	np1
,	,	y
J.T.	jt	np1
Coyle	coyle	np1
,	,	y
&;		null
C.	c	np1
Nemeroff	nemeroff	np1
,	,	y
(	(	y
Eds	ed	nn2
.	.	y
)	)	y
,	,	y
Neuropsychopharmacology	neuropsychopharmacology	np1@_nn1
:	:	y
The	the	at
fifth	fifth	md
generation	generation	nn1
of	of	io
progress	progress	nn1
(	(	y
pp.	pp	nnu2
1381	1381	mc
-	-	-
1397	1397	mc
)	)	y
.	.	y
Philadelphia	philadelphia	np1
:	:	y
Lippincott	lippincott	np1
Williams	williams	np1
and	and	cc
Wilkins	wilkins	np1
.	.	y
<p>	<p>	y
--		zz
Simon	simon	np1
,	,	y
E.J.	e.j	np1
,	,	y
&;		null
Hiller	hiller	nn1_np1@
,	,	y
J.M.	jm	np1
1994	1994	mc
Opioid	opioid	jj
peptides	peptide	nn2
and	and	cc
opioid	opioid	jj_nn1
receptors	receptor	nn2
.	.	y
In	in	ii
G.	g	np1
J.	xx_j	np1
E.	e	np1
A.	a	zz
Siegel	siegel	np1
,	,	y
(	(	y
Eds	ed	nn2
.	.	y
)	)	y
,	,	y
Basic	basic	jj
neurochemistry	neurochemistry	nn1
:	:	y
Molecular	molecular	jj
,	,	y
cellular	cellular	jj
,	,	y
and	and	cc
medical	medical	jj
aspects	aspect	nn2
(	(	y
pp.	pp	nnu2
32i-339	32i-339	mc
)	)	y
.	.	y
New	new	np1
York	york	np1
:	:	y
Raven	raven	jj_np1
Press	press	nn1
.	.	y
<p>	<p>	y
--		zz
Simon	simon	np1
,	,	y
E.J.	e.j	np1
,	,	y
Hiller	hiller	nn1_np1@
,	,	y
J.M.	jm	np1
,	,	y
&;		null
Edelman	edelman	np1_nn1
,	,	y
1	1	mc1
.	.	y
1973	1973	mc
Stereospecific	stereospecific	jj
binding	binding	nn1@_jj
of	of	io
the	the	at
potent	potent	jj
narcotic	narcotic	nn1
analgesic	analgesic	nn1
3Hetorphine		fo
to	to	ii
rat	rat	nn1
brain	brain	nn1
homogenate	homogenate	nn1
.	.	y
Proceedings	proceedings	nn2
of	of	io
the	the	at
National	national	jj
Academy	academy	nn1
of	of	io
Sciences	science	nn2
USA	usa	np1
,	,	y
70	70	mc
,	,	y
1947-1949	1947-1949	mcmc
.	.	y
<p>	<p>	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
and	and	cc
a	a	at1
synaptic	synaptic	jj
plasma	plasma	nn1
membrane	membrane	nn1
fraction	fraction	nn1
of	of	io
rat	rat	nn1
cerebral	cerebral	jj
cortex	cortex	nn1
.	.	y
Acta	acta	np1@
Pharmacoligica		np1
Toxicoligica		np1
,	,	y
32	32	mc
,	,	y
317-320	317-320	mcmc
.	.	y
<p>	<p>	y
--		zz
Volkow	volkow	nn1_np1
,	,	y
N.D.	nd	np1
,	,	y
&;		null
Fowler	fowler	np1
,	,	y
J.S.	js	np2
2000	2000	mc
Addiction	addiction	npx
,	,	y
a	a	at1
disease	disease	nn1
of	of	io
compulsion	compulsion	nn1
and	and	cc
drive	drive	vv0_nn1
:	:	y
Involvement	involvement	nn1
of	of	io
the	the	at
orbitofrontal	orbitofrontal	jj
cortex	cortex	nn1
.	.	y
Cerebral	cerebral	jj
Cortex	cortex	nn1
,	,	y
10	10	mc
,	,	y
318-325		mcmc
.	.	y
<p>	<p>	y
--		zz
Volkow	volkow	nn1_np1
,	,	y
N.D.	nd	np1
,	,	y
&;		null
Li	li	np1
,	,	y
T.K.	tk	np1
2004	2004	mc
Drug	drug	nn1
addiction	addiction	nn1
:	:	y
The	the	at
neurobiology	neurobiology	nn1
of	of	io
behavior	behavior	nn1
gone	go	vvn
awry	awry	rl
.	.	y
Nature	nature	nn1
Reviews	review	vvz
Neuroscience	neuroscience	np1
,	,	y
5	5	mc
,	,	y
963-970		mcmc
.	.	y
<p>	<p>	y
--		zz
Wise	wise	np1
,	,	y
R.A.	r.a	nna
1980	1980	mc
Action	action	nn1
of	of	io
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
on	on	ii
brain	brain	nn1
reward	reward	nn1
systems	system	nn2
.	.	y
Pharmacology	pharmacology	np1@_nn1
Biochemistry	biochemistry	np1_nn1
and	and	cc
Behavior	behavior	np1_nn1
,	,	y
13	13	mc
(	(	y
Suppl	suppl	vv0_np1_nn1
1	1	mc1
)	)	y
,	,	y
213-223		mcmc
.	.	y
<p>	<p>	y
By	by	ii
George	george	np1
F.	f	np1
Kooe		np1
and	and	cc
Eric	eric	np1
J.	xx_j	np1
Simon	simon	np1
<p>	<p>	y
George	george	np1
F.	f	np1
Koob	koob	np1
,	,	y
Ph.D.	ph.d	nna
,	,	y
is	be	vbz
Professor	professor	nn1
and	and	cc
Chairman	chairman	nn1
of	of	io
the	the	at
Committee	committee	nn1
on	on	ii
the	the	at
Neurobiology	neurobiology	nn1
of	of	io
Addictive	addictive	jj
Disorders	disorder	nn2
at	at	ii
The	the	at
Scripps	scripps	np1_nn2
Research	research	nn1_vv0@
Institute	institute	nn1
and	and	cc
Adjunct	adjunct	nn1
Professor	professor	nn1
in	in	ii
the	the	at
Departments	department	nn2
of	of	io
Psychology	psychology	nn1
and	and	cc
Psychiatry	psychiatry	np1_nn1
and	and	cc
the	the	at
Skaggs	skaggs	np1
School	school	nn1
of	of	io
Pharmacy	pharmacy	np1_nn1
and	and	cc
Pharmaceutical	pharmaceutical	jj
Sciences	science	nn2
at	at	ii
the	the	at
University	university	nn1
of	of	io
California	california	np1
,	,	y
San	san	np1
Diego	diego	np1
.	.	y
He	he	pphs1
specializes	specialize	vvz
on	on	ii
the	the	at
neurobiology	neurobiology	nn1
and	and	cc
theoretical	theoretical	jj
constructs	construct	nn2
of	of	io
drug	drug	nn1
addiction	addiction	nn1
,	,	y
reward	reward	nn1_vv0@
,	,	y
and	and	cc
stress	stress	nn1
.	.	y
<p>	<p>	y
Dr.	dr	nnb
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
New	new	np1
York	york	np1
University	university	nn1
Medical	medical	jj
Center	center	nn1
.	.	y
Dr.	dr	nnb
Simon	simon	np1
's	's	ge
laboratory	laboratory	nn1
has	have	vhz
done	do	vdn
pioneering	pioneering	jj
research	research	nn1
on	on	ii
the	the	at
mode	mode	nn1
of	of	io
action	action	nn1
of	of	io
narcotic	narcotic	nn1
analgesics	analgesic	nn2
.	.	y
In	in	ii
1973	1973	mc
his	his	appge
laboratory	laboratory	nn1
,	,	y
and	and	cc
others	others	nn2
,	,	y
discovered	discover	vvd
the	the	at
opiate	opiate	nn1
receptors	receptor	nn2
in	in	ii
the	the	at
brain	brain	nn1
.	.	y
He	he	pphs1
and	and	cc
his	his	appge
collaborators	collaborator	nn2
have	have	vh0
continued	continue	vvn
to	to	to@_ii
work	work	vvi_nn1
on	on	ii
opiate	opiate	nn1
receptors	receptor	nn2
and	and	cc
endogenous	endogenous	jj
opioid	opioid	jj_nn1
peptides	peptide	nn2
and	and	cc
have	have	vh0
published	publish	vvn
250	250	mc
papers	paper	nn2
in	in	ii
excellent	excellent	jj
journals	journal	nn2
.	.	y
He	he	pphs1
coined	coin	vvd
the	the	at
widely	widely	rr
used	used	jj_vvn
term	term	nn1
"	"	y
endorphins	endorphin	nn2
.	.	y
"	"	y
<p>	<p>	y
